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Abstract

Tele-ophthalmology is a screening alternative that facilitates compliance to eye care
guidelines regardless of geographic constraints, promoting adequate delivery of health
services to underserved communities. We conducted a systematic review and metaanalysis to assess the diagnostic performance of tele-ophthalmology (TO) programs for
the detection of diabetic retinopathy (DR), and used decision-tree modeling to explore
its cost-effectiveness compared to in-person examination in a semi-urban scenario.
From the 1,060 articles initially identified, 23 met inclusion criteria for data extraction.
The diagnostic performance of TO for the detection of any DR and referable DR met the
minimum diagnostic criteria by the Canadian Ophthalmological Society (sensitivity
>80%, specificity >90%). Interpretation of clinical significance is limited due to significant
heterogeneity. Considering a semi-urban scenario, the incremental cost per additional
case of any DR detected after the introduction of pharmacy-based TO was $314.1, being
more costly and more effective than in-person examination.
Keywords
Tele-ophthalmology, tele-medicine, diabetic retinopathy screening, digital photography,
diagnostic accuracy, meta-analysis, economic analysis, decision tree modeling.
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Chapter 1 Introduction

2

1

Introduction

Diabetic retinopathy (DR) is a sight-threatening condition involving the retinal
microvasculature in type I and type II diabetic patients.1 Although treatments such as
laser photocoagulation and anti-VEGF therapy can mitigate the progression of DR, it
remains one of the main causes of vision loss and blindness in the working age
population in industrialized countries.2,3 Screening for DR is a key component for
timely treatment delivery, and it remains one of the main challenges to reduce cases
of vision loss.4,5 Diabetic patients tend to be non-compliant to eye examination
guidelines, as less than 50% attend annual screening as advised by the American
Academy of Ophthalmology.6,7 Low availability of eye care professionals to assess
DR, lack of awareness about the effects of diabetes on vision, and reluctance of
undergo a dilated eye examination are among the main reasons for
noncompliance.8,9
Tele-ophthalmology has emerged as a promising alternative to in-person eye
examination for DR screening.10 It uses digital photography and electronic
communications to promote eye examination in non-specialized settings, where the
patient and the specialist are in different geographical locations11. This system has
the potential to facilitate eye screening delivery to diabetic patients, while
transferring some of the workload of routine eye care examinations from specialists
to other settings.12
Achieving a high diagnostic accuracy is an important factor for success in a teleophthalmology screening program.13 Factors such as pharmacologic dilation,
number of fields and population characteristics may influence the effectiveness of
the program.14 The first objective of the present study was to quantitatively
synthesize the evidence available regarding the diagnostic accuracy of teleophthalmology strategies for DR screening, and shed some light about screening
factors that may play a role in the correct identification of patients with DR. The
second objective was to conduct a cost-effectiveness analysis of a pharmacy-based
tele-ophthalmology program in type I and II diabetic adults from non-urban locations
of Southern Ontario.
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1.1 Structure of thesis document
In compliance with the standards outlined by Western University School of Graduate
and Postdoctoral studies, this thesis is presented in the integrated-article format. A
comprehensive review of the related literature is covered in Chapter 2. The work
comprising the thesis objectives is presented as two manuscripts. Chapter 3,
Estimating the Diagnostic Accuracy of Tele-ophthalmology for Diabetic Retinopathy
Screening: A meta-analysis, addresses the first objective, while Chapter 4, Costeffectiveness Analysis of diabetic Retinopathy Screening With Pharmacy-based Teleophthalmology Versus In-person Examination, explores the second objective. Lastly,
Chapter 5, Integrated Discussion, summarizes the main findings of this thesis in its
global context.
1.2 Literature cited
1. COGAN DG, TOUSSAINT D, KUWABARA T. Retinal vascular patterns. IV. Diabetic
retinopathy. Archives of ophthalmology. 1961;66:366–78. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/13694291. Accessed February 25, 2013.
2. Chistiakov DA. Diabetic retinopathy: pathogenic mechanisms and current
treatments. Diabetes & metabolic syndrome. 5(3):165–72. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/22813573. Accessed February 25, 2013.
3. Rodriguez J, Sanchez R, Munoz B, et al. Causes of blindness and visual impairment
in a population-based sample of U.S. Hispanics. Ophthalmology. 2002;109(4):737–
43. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11927431. Accessed January
22, 2013.
4. Gillow JT, Gray JA. The National Screening Committee review of diabetic
retinopathy screening. Eye (London, England). 2001;15(Pt 1):1–2. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/11318268. Accessed March 31, 2013.
5. Squirrell DM, Talbot JF. Screening for diabetic retinopathy. JRSM. 2003;96(6):273–
276. Available at: http://jrsm.rsmjournals.com/cgi/doi/10.1258/jrsm.96.6.273.
Accessed May 10, 2012.
6. American Academy of Ophthalmology. Diabetic Retinopathy Preferred Practice
Pattern Guidelines. San Francisco, CA; 2008:39. Available at:
http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=d0c853d3-219f487b-a524-326ab3cecd9a.
7. Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy.
Indian journal of ophthalmology. 60(5):428–31. Available at:
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http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3491270&tool=pmcent
rez&rendertype=abstract. Accessed January 10, 2013.
8. Puent BD, Nichols KK. Patients’ perspectives on noncompliance with diabetic
retinopathy standard of care guidelines. Optometry (St. Louis, Mo.).
2004;75(11):709–716. Available at:
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed6&NEWS=N&A
N=15597813.
9. Moss SE, Klein R, Klein BE. Factors associated with having eye examinations in
persons with diabetes. Archives of family medicine. 1995;4(6):529–34. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/7773429. Accessed April 9, 2013.
10. Yogesan K, Constable IJ, Eikelboom RH, Saarloos PP. Tele-ophthalmic screening
using digital imaging devices. Australian and New Zealand Journal of Ophthalmology.
1998;26:S9–S11. Available at: http://doi.wiley.com/10.1111/j.14429071.1998.tb01385.x. Accessed April 7, 2013.
11. Kawasaki S, Ito S, Satoh S, et al. Use of Telemedicine in Periodic Screening of
Diabetic Retinopathy. Telemedicine Journal and e-Health. 2003;9(3):235–239.
Available at:
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed6&NEWS=N&A
N=2003432464.
12. JN H, Craney L, Nagendran S, CS N. Towards comprehensive population-based
screening for diabetic retinopathy: operation of the North Wales diabetic
retinopathy screening programme using a central patient register and various
screening methods. Journal of Medical Screening. 2006;13(2):87–92. Available at:
http://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=2009220293&si
te=ehost-live.
13. Whited JD. Accuracy and reliability of teleophthalmology for diagnosing diabetic
retinopathy and macular edema: a review of the literature. Diabetes technology &
therapeutics. 2006;8(1):102–11. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/16472057. Accessed April 8, 2013.
14. E Z-GI, Ran Z. Telemedicine in diabetic retinopathy screening. International
ophthalmology clinics. 2009;49(2):75–86. Available at:
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN
=19349788.
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Chapter 2 Literature review, Thesis rationale and Thesis
objectives

6

2.1 Literature review
Diabetic retinopathy (DR) is a serious microvascular complication in diabetic patients,
which can have a sudden and debilitating impact on visual acuity, eventually leading
to blindness.1,2 Features of diabetic retinopathy begin with micro-aneurysms and
progress into exudative changes, ischemic changes, venous beading and abnormal
vessel growth.3 Improved medical care over the last three decades (intensive insulin
therapy and tight blood glucose control) has reduced the progress of visionthreatening retinopathy.4 However, it remains a challenge to prevent retinopathy
and other complications before the onset of advanced stages of disease to provide a
timely treatment that could lead to reducing vision loss by 50%.5,6 To achieve this
goal, it is necessary to have scheduled regular eye examinations to ensure a reliable
detection at time when treatment (e.g. laser therapy, or anti-VEGF treatments) is
most effective. Lack of compliance to screening guidelines, limited availability of
retina specialists and ophthalmologists in several geographic areas and
socioeconomic barriers are the main challenges to improve visual outcomes in
diabetic patients.7,8
2.1.1 Natural History of diabetic retinopathy
Although fundamental causes are uncertain, exposure to elevated glucose and other
risk factors initiates a cascade of biochemical and physiological changes that take
place before the onset of vascular lesions in patients with clinically normal retinas.9
Normal vision relies on the perfect cell-cell communication among epithelial cells on
the retina, mainly neuronal, glial, microglial, vascular and pigmented cells (Figure
2.1).4 Vascular changes in diabetic patients such as increased retinal flow and
permeability of small vessels, if left uncontrolled, could lead to glucose-mediated
microvascular damage in retinal structures conducting to progressive vision loss.2
While the interval between diabetes diagnosis and development of any retinopathy
varies from 4 to 7 years ( or longer), functional and anatomic changes do occur
shortly after the onset of insulin-deficient diabetes, corresponding to the preclinical
retinopathy stage.10–12 During this stage, early histological changes such as pericyte
loss and basement membrane thickening are the main cellular events affecting
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retinal function, but are only detectable by histological examination and cannot be
identified clinically. These changes affect the growth and repair of endothelial cells in
the retinal vascular system; pericyte loss in particular affects normal capillary
perfusion, which increases membrane permeability and causes extravasation of
intravascular fluid.9,13,14 To prevent the progression of this early phase to more
severe vascular lesions, it is recommended that patients with normal-appearing
retinas and good vision should already have a specific screening schedule as well as a
solid preventive treatment to control for other known risk factors that could
accelerate the onset of DR.3,4 These individuals also represent an important
therapeutic opportunity since they will have a better response to intensive therapy
and an increased chance to preserve vision loss.4

Figure 2.1 Anatomy of the retina
As preclinical retinopathy remains undetected, the combined effect of pericyte loss
and expression of angiogenic factors by nonvascular retinal cells leads to the onset of
clinical manifestations of nonproliferative diabetic retinopathy (NPDR), such microaneurysms and intraretinal microvascular abnormalities localized within the retina
(IRMA).4,13 Other defects such as capillary dilation, nonperfusion and leakage are also
developed predominantly in the posterior fundus temporal to the macula,
compromising neuronal and glial cell integrity which in turn have a negative impact
in neurotransmission.4,15 As DR progresses, new retinal vessels in the optic disc are
formed as a consequence of the permanent expression of VEGF factor, cytokines and
other components involved in inflammatory response. When neovascularization and
retinal vasodilation beading takes place, the disease has progressed to proliferative
diabetic retinopathy (PDR). The cumulative effect of vascular and neural alterations
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taking place in both the retina and optic nerve (e.g. macular edema, retinal
detachment, optic neuropathy and axonal degeneration) along with presence of
media opacities lead to vision loss.16
2.1.2 Epidemiology of diabetic retinopathy
Diabetic retinopathy is recognized as a public health problem among industrialized
nations, as it remains the main cause of blindness in people aged 20 to 74 years of
age. In north American adult type 2 diabetic patients older than 40 years, 40% have
retinopathy and 8% have progressed to vision-threatening retinopathy.17 Important
risk factors include hyperglycaemia, diabetes duration and concomitant
hypertension.18 Vision-loss rates have been decreasing over the past three decades,
due to the advent of photocoagulation treatment for DR patients and newer anti
VEGF treatments. However, a timely identification of at-risk patients is of great
importance for adequate treatment delivery.19
2.1.2.1 Prevalence
In many industrialized countries, DR is the most frequent cause of vision impairment
in both the elderly and the working-age population20. A recent meta-analysis
conducted by Yaw JWY and colleagues, revealed that the global age-adjusted
prevalence of any DR is 34.6% (95% CI: 34.5-34.8) among diabetic patients21. A
higher prevalence of any DR among type I DM patients was also found (77.3%), when
compared to that of type II DM counterparts (35.2%). Similarly, prevalence estimates
were higher in African-Americans (49.5%) and lower in Asians (19.1%); moreover, no
significant gender difference in DR prevalence was found 21. Other studies conducted
in United States and Australia have reported lower prevalence22. In United States the
estimated prevalence of any DR for diabetic individuals over 40 years is 28.5%,
whereas in Australia is 21.9% for individuals over 25 years with type II diabetes23,24.
Of important note, rural communities seem to have particularly high DR prevalence.
A study conducted in rural China named The Handan Eye Study, showed a
prevalence of any DR of 40% in diabetic patients over 30 years of age25.
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Recent studies conducted in Canada have taken place in Alberta, James Bay and the
Metis Nation, revealing conflicting prevalence estimates. Studies such as The
Southern Alberta Study for Diabetic Retinopathy (SASDR)26 conducted in both urban
and rural areas revealed a prevalence of any DR of 40%, almost two-fold greater
than the one reported by Nathoo and colleagues (27.2%) for rural northern
Alberta27. Similarly, a study conducted in Alberta First Nations communities by
Rudnisky and colleagues using a tele-ophthalmology screening strategy, found a
prevalence of any DR of 20.71%28. Such differences might be due to selection bias or
might reflect a true difference in disease burden.
Although it has been proposed that native communities are more susceptible to
develop diabetes-derived vascular complications such as DR29,30, the SASDR study did
not find differences in prevalence of any DR between native and non-native
Canadians26.
2.1.2.2 Incidence
Very few population-based studies have reported the incidence of DR; the Wisconsin
Epidemiologic Study of Diabetic Retinopathy (WESDR) is perhaps the most widely
known31. This study conducted in the United States, included type I and II DM
patients from 11 counties in south central Wisconsin with the main objective of
providing a stable estimate of risk of DR according to age group (less than 30 years
and equal or older than 30 years)32. The results showed that, in a 10-year interval
the overall incidence of DR was 74%; 17% of patients diagnosed with DR at baseline
developed PDR during that same timeframe33. After 25 years of follow-up (19801982 to 2005-2007), almost all patients with type I diabetes developed DR (97%)
from which 42% progressed to PDR34.
A recent study conducted in England by Jones and colleagues, included type I and II
diabetic patients screened by the Central Norfolk Diabetic Retinopathy Screening
Service between 1990 and 200635. At baseline, 20.5% of patients had at least preproliferative retinopathy. Overall incidence rates of any DR after 5 and 10 years of
follow-up were 41.3% and 84.7%, respectively. Likewise, after 10 years of follow-up
11% of patients with pre-proliferative retinopathy at baseline developed PDR. Unlike
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the WESDR study results, the incidence rate of PDR was lower, probably due to a
selective exclusion of high-risk patients that were referred to a specialist, and thus
removed from the screening cohort35.
While the trend of DR incidence for type I and II diabetic patients is not well
established, there is evidence that progression to PDR has been decreasing
throughout time6. A systematic review conducted by Wong and collaborators,
included 28 studies from 1975 to 2008 to determine temporal trends and rates of
progression of DR to PDR36. Among studies that reported the incidence rate after 4
years of follow-up, the pooled incidence of PDR was 11%. After stratifying by time
points, it was found that 19.5% of patients developed PDR in 1975-1985 in contrast
to just 2.6% in the 1986-2008 cohort36. Such difference might be partially explained
by the improvement in DR screening methods and treatment guidelines for diabetic
patients, as well as a better glycemic control in recent years37.
2.1.2.3 Risk of blindness and severe vision loss (SVL)
Vision loss is the most important functional consequence of DR. Despite the
availability of novel treatments to prevent severe vision impairment from DR, it is
clear that blindness from diabetes remains a public health concern in most
countries31,38. A meta-analysis conducted by Wong and associates, found a rate of
severe vision loss (visual acuity <5/200) of 2.6% in studies published between 1986
and 200836. Moreover, SVL was more likely to develop in patients with untreated DR
at baseline, which highlights the importance of an early diagnosis and a timely
intervention36,39,40. .
Also important is the burden of legal blindness (<20/200) and visual disability
(<20/70) due to advanced forms of DR. In the WESDR study for example, 3.6% of
insulin requiring participants were legally blind (visual acuity <20/200 in the better
eye) at the baseline examination34,41. Even mild forms of visual impairment have a
considerable impact on quality of life, as patients with impaired visual acuity report
low socialization,42 emotional distress and difficulties in physical function related to
driving and distance vision.43 As a result, these debilitating ramifications of loss in
visual acuity may lead to a significant reduction in the functional status of the
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patient, taking a toll to society.9 Thus, prompt classification of DR and appropriate
treatment according to DR severity becomes crucial to reduce its progression and to
subside the impact on visual acuity.
Evidence of decreasing vision loss rates has been reported in recent studies 44. Klein
et al, reported a decrease in vision loss incidence rates in more recently diagnosed
type I diabetic patients (annual incidence rate 1.19% in early 1980’s vs. 0.30% in mid2000’s), which might be due to a combined effect of better glucose controls, timely
treatment interventions and a lower incidence of PDR45.
2.1.2.4 Risk factors
2.1.2.4.1 Modifiable factors
 Hyperglycemia
Glycemic control is currently considered an important predictive factor for DR,
although its influence in onset and progression of DR wasn’t established until early
1980’s.31,40 Epidemiological findings from large population studies such as WESDR,41
the Diabetes Control and Complications Trial (DCCT),46 and the UK Prospective
Diabetes Study (UKPDS)47 helped to determine whether the level of hyperglycemia
influences the risk of retinopathy. Specifically, evidence from the WESDR study
showed that for every 1% decrease in glycosylated hemoglobin A1 level (HbA1c)
there was an association with an 18% decrease in the 21-year progression to PDR in
insulin requiring subjects.34 This study also provided evidence that glycemic control
was a significant predictor of 10-year rate of PDR, in both type I and II diabetic
patients.48
Findings from the WESDR study were further confirmed by subsequent outcomes
from the DCCT (Type I DM patients) and the UKPDS (Type II DM patients) trials. In
the DCCT trial, it was proven that intensive glycemic control (median HbA1c, 7.2%)
led to a reduction of 76% (95% CI:62-85) in the development of DR among insulinrequiring patients without DR at baseline.46 Similarly, patients in the intensive
glycemic treatment group had a lower progression rate from early to advance DR by
54% (95%CI: 39%-66%), as compared to patients in the conventional treatment
group. This means that subjects with HbA1c levels of 10% have a 5-fold increase risk
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of DR progression, as compared to patients with 7% HbA1c levels.46,49,50 In line with
these findings, the UKPDS reported equivalent findings for type II diabetic patients.47
After 10 years of follow-up, patients in the treatment-intensive group (dietary
restriction plus medication) had a 25% (95%CI: 7%-40%) risk reduction of
microvascular events (including progression of DR), when compared with the
conventional treatment group (diet only).51,52 Levels of HbA1c were also lower in
treatment intensive patients (7% vs. 7.9%) than in their counterparts.52
Altogether, these studies provided evidence that intensive glycemic control is a
determinant factor for reducing the risk of development and progression of DR in
both type I and II diabetic patients. In fact, they founded the basis for the American
Diabetes Association guidelines for glycemic control to reach a target level of HbA1c
of 7% for diabetic patients.40
 Hypertension
It is hypothesized that hypertension might contribute to an increase of retinal blood
flow, which in turn promotes the onset of DR.53 Some epidemiologic studies have
found evidence of an association between hypertension and DR progression,
although its influence in DR onset is not well established yet, especially in type I
diabetic subjects.5,20 In the WESDR study, blood pressure was related to the
progression of PDR in insulin-dependent patients (HR, 1.3 per 10 mmHg; 95% CI:
1.16-1.46; p-value < 0.001), but hypertension at baseline was not associated with
incidence of DR (HR, 1.1; 95%CI: 0.86-1.44; p-value, 0.42) in type I diabetic patients.34
In contrast, the UKPDS study randomized eligible type II diabetic patients with
borderline or mild hypertension to receive tight blood pressure control (<150/<85
mmHg), or conventional control (<180/<105 mmHg).47 Patients having a tight control
had a 34% reduction (99%CI: 11%-50%) in the progression of DR, and a 35%
reduction in laser photocoagulation compared with patients in the conventional
control group52,54.
 Other risk factors
Results from some epidemiological studies have found that other modifiable factors
such as dyslipidemia, obesity and inflammatory markers are somewhat associated
with DR20,37. However, findings have been inconsistent and their particular role in the
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pathogenesis of DR has not been yet elucidated. Although studies have failed to
demonstrate an association of DR progression and total cholesterol levels, data from
two large cohort studies55,56 have found that high serum lipids at baseline are related
to the development of hard retinal exudates. Specifically, increasing triglycerides and
lower HDL cholesterol were reported to be potential risk factors for the progression
of DR in type I diabetic patients57,58. Such findings were also confirmed by a crosssectional analysis of insulin-requiring European patients, in which subjects with
elevated triglyceride levels presented a doubled risk of DR progression, when
compared to patients in the lowest triglyceride quartile59.
The relationship between body mass index (BMI) or waist to hip ratio and DR
progression is still inconclusive. Some studies have found that higher BMI and neck
circumference are independently associated with the presence and severity of
DR60,61. In contrast, large scale studies such as WESDR have suggested a protective
role of BMI in DR progression among type I patients. It is evident that more research
is needed to clarify the role of obesity in DR onset and progression62. Similarly,
evidence regarding the role of inflammatory markers as risk factors for DR is at an
early stage, in which markers of inflammation such as C-reactive protein, interleukin6 and soluble intercellular adhesion molecule 1 have been associated with
retinopathy and proposed as novel therapeutic targets as well60,63. Compelling
epidemiologic evidence is necessary to understand the role of markers of
inflammation in DR pathogenesis and the possibilities of clinical use as therapeutic
targets for retinopathy prevention.
2.1.2.4.2 Non-modifiable factors
 Duration of diabetes
The role of diabetes duration in the development of DR is well established, and has
been consistently demonstrated in several studies.5,6,20,64,65 For instance, two
population studies conducted in the United States reported increased DR among
patients with ≥ 15 years of diabetes. The Los Angeles Latino Eye Study (LALES)
reported a four-fold increased incidence of DR in the first eye for patients with more
than 15 years of diabetes as compared to individuals with newly diagnosed
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individuals (p=0.004).64 In line with these findings, Harris and collaborators showed a
higher prevalence of DR in type II diabetic patients with 15 or more years since
diagnosis versus subjects with less than 5 years of diabetes (36% and 11.8%
respectively, p <0.001).66
 Ethnicity
Research studies have demonstrated some disparity in the prevalence and severity
of DR among ethnic groups, which sometimes has been independent from other
known risk factors.6,67 Some studies conducted in the United States have reported
that members from Hispanic and African American communities have a greater risk
of DR when compared to non-Hispanic white counterparts.64,66,68 For example, the
Multi-ethnic study of Artherosclerosis (MESA) reported a higher DR prevalence (p=
0.01) among black and Hispanic people (36.7% and 37.4%, respectively) than in white
subjects (24.8%). Although ethnic origin was not an independent predictor of DR,
researchers have speculated that genetic factors might explain the excess risk of DR
in some ethnic groups.17,49,51,52 In a subsequent analysis, the DCCT study investigators
assessed familial associations and risk of DR in more than 300 participants69. It
showed an increased risk of severity of retinopathy among relatives of retinopathypositive patients when compared to relatives of retinopathy-negative subjects (OR=
3.1; p < 0.05).69
Altogether, such evidence suggests that differential genetic predisposition to
microvascular damage, or even intrinsic cultural factors among ethnic groups might
have an underlying role in the development of DR. However, greater exposure to
hyperglycemia and higher frequency of risk factors (i.e. poor glycemic control) in
African Americans and Hispanic individuals versus white subjects might also account
for reported differences in DR development among ethnic groups66.
 Other non-modifiable risk factors
It is speculated that hormone elevation levels occurring after puberty are positively
associated with retinopathy70. Studies conducted in the past two decades reported
that prepubertal duration of diabetes is related to increasing the delay in the onset
of microvascular complications, such as DR in insulin-requiring patients.71–73 A
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subsequent analysis derived from the WESDR study, reported that diabetes duration
after menarche was associated with an increased risk of retinopathy compared with
diabetes duration prior menarche (OR=3.15; p< 0.05).71 Similarly, pregnancy has
been associated with an increased development and progression of DR, especially in
type I diabetic patients.74,75 In a longitudinal analysis derived from the DCCT study,
pregnant women (type I diabetes) had 1.6 to 2.4-fold increased risk of retinopathy
compared to non-pregnant counterparts, being the highest risk at the second
semester.76 Notwithstanding, DR developed during pregnancy shows a 30% to 50%
rate of spontaneous regression after delivery with no long-term consequences.77
2.1.3 Clinical assessment of diabetic retinopathy
2.1.3.1 Screening techniques
A comprehensive screening evaluation for DR should include intraocular pressure
and visual acuity estimations, as well as retina examinations for the presence of
neovascularization.78 The main potential screening modalities for DR assessment are
ophthalmoscopy (direct and indirect), fluorescein angiography, slit-lamp
biomicroscopy and mydriatic or non-mydriatic camera-based screening.79 According
to the Canadian Ophthalmology Society evidence-based guidelines, screening
alternatives for DR grading should accomplish a sensitivity of at least 80% and
specificity between 90% and 95%, if performed by a trained examiner.78 Likewise, a
widely used clinical standard proposed by the British Diabetic Association Working
Group in 1997 specifies that methods of screening for DR should match the 80% and
95% specificity standards, keeping in mind that lower effectiveness values imply
potential costs for the healthcare system and missed treatment opportunities.80
From the mentioned alternatives, ophthalmoscopy and slit-lamp biomicroscopy are
traditionally used for community-based screening. However, ophthalmoscopy shows
a significant variation on the effectiveness depending on the healthcare professional
that conducts the examination.81 For example, studies that evaluated the
effectiveness of screenings by optometrists and general practitioners showed that
sensitivity levels for detecting sight-threatening retinopathy ranged between 25%
and 80%, being optometrists more effective than general practitioners.82–84 Similarly,
studies using undilated ophthalmoscopy screening conducted by
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nonophthalmologists reported poor performance, with a sensitivity as low as 50%
for the detection of PDR.81 Alternatively, the best screening approach for grading DR
is dilated slit-lamp biomicroscopy, assessed by a retina specialist or senior
ophthalmologist with a 90D or 78D lens. This technique has proven to be highly
effective, achieving sensitivity and specificity values of 87% and 94%,
respectively.83,85
2.1.3.2 Screening and prevention of DR
DR fulfills the World Health Organization (WHO) criteria for screening;86 these
criteria revolve around three critical components: Disease, screening test, diagnosis
and treatment.
Disease
DR is an important public health concern,87 with a recognizable presymptomatic
stage and a natural history well described in the literature.2 It is widely accepted that
DR presents a long preclinical phase that may last up to 7 years, during which the
patient cannot detect any vision changes.10-12 Usually, the patient seeks medical care
after severe retinal damage has occurred, for which treatment may not be effective.
9

Therefore, the detection of early stages of DR through screening facilitate adequate

treatment delivery, which is translated to cases of blindness prevented. For example,
some districts in Great Britain with long-standing DR screening programs have
reported that DR is no longer the main cause of blindness amongst working-age
individuals, as opposed to other settings that do not have a consistent screening
program in place.7
Screening test
Several screening methods can be used for DR examination. Screening typically
includes direct/indirect ophthalmoscopy, slit-lamp biomicroscopy or digital fundus
photography. Their performance may vary depending on use of pharmacologic
dilation, the grade of expertise of the examiner and threshold positivity. For the
detection of sight-threatening retinopathy, mydriatic digital fundus photography
results interpreted by an expert reader yield a sensitivity and specificity of over
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80%.82 These screening techniques are not invasive and do not cause the patient any
harm; however, pharmacologic mydriasis may cause temporary blurred vision and
increase the risk of temporary open-angle glaucoma.39 Nevertheless, the benefits of
early detection of DR cases outweight the potential (and reversible) harm of openanle glaucoma.9
Diagnosis and treatment
Several landmark clinical trials32,88,89 have shown the clinical benefits of timely and
accurate screening that facilitates treatment delivery and prevents blindeness due to
DR. For example, the Diabetic Retinopathy Study (DRS) demonstrated that panretinal
photocoagulation reduces the risk of vision loss by 50% and 16% in patients with
macular edema and PDR, respectively.90 Such findings were later confirmed by the
ETDRS study in older-onset diabetic patients.91 Even novel therapies, such as antiVEGF treatments have shown improvement in visual acuity in patients with diabetic
macular edema, a serious complication derived from the progression of DR.92 More
recent studies on anti-VEGF treatments have shown that not only patients under this
therapy have a long-lasting improvement in visual acuity, but also have significant
regression of retinal neovascularization and reduced retinal thickness.93 Therefore,
an early intervention for DR treatment does translate in clinical improvement by
preventing cases of blindness and severe vision loss in patients with moderate PDR.90
In fact, evidence-based models have shown that with proper screening and
treatment, 6% of patients would be prevented from blindness within a year and up
to 34% within 10 years..
Finally, DR screening programs have proven to be cost-effective in economic
modelling studies, resulting in substantial budget savings for the healthcare
provider.94,95
Screening goals and challenges
The main goal of a screening program for DR is the detection of sight-threatening
disease, in which the detection of any retinopathy is of secondary benefit but may
act as an early proxy of the former.96 Examination guidelines have been developed
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by organizations such as the American Academy of Ophthalmology (AAO)97 and the
American Diabetes Association (ADA)19 which have been largely based on
retinopathy severity. According to ADA’s latest guidelines, an immediate eye
examination is recommended for newly diagnosed type II diabetic patients, whereas
type I patients can have their first examination within 3 to 5 years of diagnosis.
Annual or biannual eye examination is recommended in absence of complications,
with more frequent examinations in case of abnormal findings.19 Likewise, the AAO
formulates the same differential recommendation for type I and II diabetic patients,
with an annual follow-up examination for both groups.97
Adherence to examination recommendations has been less than satisfactory, with a
30%-60% compliance rate that varies across different settings98. For instance,
adherence rates to vision guidelines in North America were less than 50% during the
past two decades;8 unfortunately, reported rates do not yet show an increasing
adherence trend over time.99 Studies also show that translation of research into
practice and adoption of examination guidelines have been delayed by compliance
barriers, in areas such as community education and finance.100 Among these studies,
the Diabetic Retinopathy Awareness Program (DRAP) trial101 conducted in the US,
reported a nonadherence rate to AAO and ADA guidelines of 30% (n= 813/2308). It
also suggested four main factors associated to poor compliance: healthcare provider,
population demographics, diabetes type and duration and education.101 Low
screening rates translates into negative implications for the quality of life of diabetic
patients, representing potential expenditures to their clinical care, lost productivity
and lost opportunities for vision loss prevention.8
Overall, this evidence supports the need to improve vision care practices in diabetic
patients, with greater emphasis on target groups at high-risk of nonadherence.100,101
These groups are typically from rural or remote areas and have a low level of
awareness about vision complications of diabetes; improved access to healthcare
(practice/provider performance) and more detailed information about DR
complications would increase screening attendance.102,103
2.1.3.3 Grading of diabetic retinopathy severity
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Currently, there are many validated DR grading scales that are applied widely in
clinical and research settings, which are based on the identification of key
microvascular abnormalities from each DR stage (Figure 2.2).12,104,105 Among
available guidelines, the Airlie House classification is universally accepted in research
settings and publications, for it has demonstrated a satisfactory reproducibility and
validity.88 It is based on seven standard 30-degree photographic fields, yielding an
accurate representation of the retinal status; an extensive standard set of more than
11 DR definitions is employed to classify DR severity in patients.88 In spite of its use in
clinical trials as the “gold standard” for DR screening, the implementation of the
Modified Airlie House classification in the clinical setting and mass screening is
somewhat unpractical due to its complexity and meticulous definitions, which are
unnecessary and difficult to remember in clinical care.104,106 In fact, the American
Academy of Ophthalmology has found that most health professionals do not use the
full Airlie House classification scale due to its complexity.12
Consequently, several countries have adapted and simplified this classification for
general practice, resulting in a variety of validated guidelines, such as European field
guide, Winsconsin guidelines and EURODIAB protocol, which have been used in
different settings over the past decade (Figure 2.2).12,104,105 It is also common to find
published studies in which authors modify an existent grading guideline, or even
develop their own classification to grade severity of DR in their study patients.107,108
The lack of consensus regarding DR severity classification poses a challenge in
healthcare delivery and research, limiting the worldwide exchange of information
and data.109,110 For example, the comparison of screening strategies from different
settings would be inappropriate if each study used their own grading system. It also
affects the effective communication between and among primary care physicians,
nurses, ophthalmologists and other eye care providers, which would be improved if a
standard set of definitions of severity of diabetic retinopathy is universally
implemented.12,106,111
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Figure 2.2 Diabetic Retinopathy Disease Severity Scales. ETDRS= Early Treatment Diabetic
Retinopathy Study DR= Diabetic Retinopathy NPDR= Non-proliferative Diabetic Retinopathy
PDR= Proliferative Diabetic Retinopathy

In an effort to providing a single standardized practical clinical DR severity scale for
worldwide use, the AAO launched a project in 2001 to develop an optimal DR scale,
resulting in the publication of the International Clinical Diabetic Retinopathy and
Diabetic Macular Edema Disease Severity Scales in 2003.12 Based on landmark
studies such as ETDRS88 and WESDR32, this scale comprises 5 different levels of DR
disease severity according to findings of IRMA and venous beading lesions (Figure
2.2). It is expected that the system will be implemented by ophthalmologists and
other healthcare providers, who can also promote its dissemination and future
incorporation of the International DR Scale in practice guidelines.12,78,112
2.1.3.4 Gold standard for diabetic retinopathy screening
From the existing screening alternatives, ETDRS 30-degrees 7-field stereo color 35
mm slides is considered the gold standard for detection of DR.94 This technique was
initially used in the DRS trial113 (1976), later expanded in the ETDRS trial88 (1991) and
validated in subsequent studies. It consists of a set of 7 photographs taken in
different areas of the eye, including stereoscopic photographs centered on optic
disc, macula, temporal to the macula, and upper and lower poles of the disc.88 This
method allows a detailed examination of various retinal abnormalities including
micro-aneurysms, soft exudates, hard exudates and retinal haemorrhages. However,
this technique is labour intensive, time consuming (it takes several weeks from data
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acquisition to interpretation), and requires skilled photographers and sophisticated
photography equipment.114 Consequently, it becomes impractical for community
screening and is not universally used in routine clinical care.79
Despite these limitations, some experts consider the ETDRS photograph protocol as
the only accepted gold standard test for detecting diabetic retinopathy in
research,79,114,115 although this statement is not universally recognized. Validation
studies have demonstrated that slit-lamp examination by an experienced specialist is
equivalent to ETDRS photographs in the detection of referable retinopathy; hence,
slit-lamp biomicroscopy has been used as a reference standard as well. In a study
conducted by Scanlon and colleagues116 in which slit-lamp biomicroscopy performed
by an ophthalmologist was assessed against 7-field ETDRS photographs, sensitivity
and specificity values of 87.4% and 94.9%, respectively. Hence, authors concluded
that slit-lamp biomicroscopy if performed by an experienced ophthalmologist is
favourably compared with 7-field ETDRS photographs in the detection of referable
retinopathy.116 Other studies have also showed a high level of agreement (kappa
index > 0.75) between examination and 7-field ETDRS photographs for grading
severe forms of DR, with small number of disagreements of clinical significane.117,118
Given that a dual gold standard exists, diagnostic accuracy studies have reported the
use of either ETDRS photographs or slit-lamp biomicroscopy as the gold standard
test.115 Such contrast is explained by the fact that observational studies prefer slitlamp biomicroscopy as the reference standard to assess diagnostic accuracy of DR
screening alternatives, especially if the study is performed “in the field”. These
projects are often conducted in remote areas and isolated communities, where
transportation of the specialized equipment required for stereo 7-field ETDRS
photographs becomes impractical and unsuitable for large-scale screening.119,120
2.1.4 Digital retinal photography
During the past 30 years, digital photography has been introduced as an effective
alternative to ophthalmoscopy and traditional camera-based screening for DR
screening programs. With the advent of digital and mobile technology, it has
gradually become the preferred screening option, as digital cameras have technically
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improved and become less expensive.121 In addition to the advantages of camerabased screening (having an image record, review of disease progression and quality
assurance), digital images can be immediately assessed and better quality images
can be retaken if necessary.96 With digital cameras it is also possible to transmit the
images electronically to specialized centers where ophthalmologists can review them
and grade the presence and extent of DR.122
Given the advantages of digital retinal photography, a growing number of studies
have assessed its performance for DR screening in diverse settings; most results have
been promising, reporting a sensitivity and specificity of above 80%123–125 with some
exceptions, where effectiveness was lower than 60%.126 Such a contrast among
studies also show that the chosen technology (i.e type of camera, resolution, image
compression), number of fields taken and use of pharmacologic dilation might play
an important role on the effectiveness of digital retinal photography screening.127
Usually, nonmydriatic approaches have a lower sensitivity and a higher rate of
unreadable photographs than those using pharmacologic dilation. Baeza and
collaborators128 directly addressed this issue by assessing three different screening
strategies with and without pharmacologic dilation, using a nonmydriatic digital
camera. Compared with 7-field ETDRS photographs, strategies using mydriasis
achieved a sensitivity between 82%-85% and a specificity of 98% with a 2% failure
rate, whereas nonmydriatic approaches showed a sensitivity range of 67%-82% and a
specificity of 99% with a 16% failure rate.128 Of important note, the screening
strategy that used only one filed and no pharmacologic dilation had the worst
sensitivity (67%; 95%CI: 54%-80%).
In contrast, other studies have reported that the use of a single field does not affect
screening quality as long as pharmacologic dilation is used. A study conducted in
Canada119 evaluated the effectiveness of single field digital screening in an aboriginal
community at James Bay (Ontario), since this modality is very practical and easy to
perform in remote areas. Authors found that this single-field approach would be
impossible to conduct without pharmacologic dilation in this community, given the
high failure rate (> 50%). However when pharmacologic dilation was implemented,
the failure rate improve dramatically (1.5%) and effectiveness values for detecting
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referable retinopathy met the Canadian Ophthalmological Society’s standards
(sensitivity >80%, specificity between 90% and 95%).119
Although there is some evidence of the importance of pharmacologic dilation and
number of fields used in digital photography screening for DR,128,129 the extent of this
influence and the interaction between both components is not well defined.81
Moreover, the role of other technical characteristics such as camera type, resolution,
image compression and storage on digital photography screening is unclear. So far,
current guidelines from the Canadian Society of Ophthalmology and the AAO
recommend that for digital photography screening, at least two 45° fields should be
taken with pharmacologic dilation if mydriatic cameras are used, and without pupil
dilation for the nonmydriatic camera models.78,79
2.1.5 Tele-ophthalmology assessment of diabetic retinopathy (telescreening)
Tele-ophthalmology is an area of telemedicine that allows the examination of
patient’s eye problems with the patient and eye care specialist located in different
geographical areas. This method is based on the exchange of medical information
from one site to another using electronic communications.114 It has been described
as a promising alternative that improves access to screening regardless of geographic
constraints; it also reduces travel time and cost while creating new screening
opportunities in underserved communities.130
Although considered futuristic and experimental during the early 80’s, teleophthalmology has gradually evolved into a specialty that incorporates modern
technology with the potential of becoming an integral component of primary care of
diabetic patients.131 Diabetic retinopathy telehealth programs typically encompass
four elements of care: Image acquisition, image review and evaluation, patient care
supervision, and image (data) storage.132
Technical requirements may vary, depending of each screening program scope and
intent.133 In a general tele-ophthalmology program for DR screening (store-andforward model), retinal images are obtained with digital retinal cameras (mydriatic
or non-mydriatic) by a previously trained non-specialist in a remote place.114 The
data is then securely transferred to a reading center for evaluation, in which ocular
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assessment is performed by an eye specialist or a certified reader; specifications
regarding image compression, bandwidth, encryption and error checking
mechanisms are tailored according to each screening program.132 Finally, findings are
reported back to the primary care physician with the recommendation regarding the
need for referral.134
In some cases images may be of poor quality due to presence of media opacities,
small pupil size or technical difficulties.129 In telescreening for DR, unreadable images
are considered positive findings and patients must be referred for a comprehensive
evaluation.135 To overcome this issue, the use of pharmacologic agents for pupil
dilation may be incorporated in the screening protocol. However, the use of
mydriatic agents by nonophthalmic personnel may represent an issue in that adverse
events such as angle-closure glaucoma might occur, requiring the need of specialized
personnel.119,136
2.1.5.1 General tele-ophthalmology guidelines
Tele-ophthalmology is a mature telehealth specialty with well-established standards
defined by the American Telemedicine Association (ATA), which seeks to improve
healthcare delivery through telecommunications and information technology, while
eliminating barriers to the use of telemedicine.132 According to the ATA, the main
goals of a tele-ophthalmology program for DR are to “reduce the incidence of vision
loss due to DR, improve access to diagnosis and management of DR, decrease the
cost of identifying patients with DR”.135 As clearly stated by the American
Telemedicine Association135 and the American Academy of Ophthalmology97, retinal
telemedicine examination is currently not intended to replace a comprehensive eye
examination by an experienced ophthalmologist, but to act as a first-line screening
tool for DR that will filter and reduce the volume of unnecessarily referred patients.
Tele-ophthalmology systems are categorized into three groups depending on image
transmission: Real-time, store-and-forward, and hybrid. Real time transmission
involves a two-way real time video connection, whereas in store-and-forward
teleconsultation the image is first captured with a digital camera in a fixed or mobile
telescreening unit and then sent forward via electronic communications.137 Hybrid is
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the combination of the two former approaches.138 Current ocular telehealth practice
guidelines from the American Telemedicine Association are based on the store-andforward modality.135
2.1.5.2 Clinical validation of tele-ophthalmology systems
Both the AAO85 and the ATA135 have stressed the importance of performing pilot
studies for the validation of new tele-ophthalmology programs. This validation must
state the scope of the program, target population, aimed validation category and
technology used. Ideally, results should be published in a peer-review journal in
which sensitivity, specificity and agreement values are reported.132,139 It is
considered that the current benchmark for evaluating a tele-ophthalmology program
consists on the use of 7 field ETDRS photographs as the reference standard, and the
use of the International DR Disease Severity Scale as the guideline for DR
classification.12,88
To outline a standard for the validation process, the ATA recently published the
second edition of “Telehealth practice recommendations for diabetic
retinopathy”135, in which four categories for validation of tele-ophthalmology
programs for DR are documented (Table 2.1). Each one differs in hardware and
software technology requirements, the level of expertise of staffing and support, and
clinical outcomes. Those programs with low thresholds for referral need not follow
strict DR classifications and technological requirements are simpler compared to
those programs that seek to discriminate level of DR.140 Independently of the
validation category, tele-ophthalmology programs should have less than 10% rate of
unreadable images.78
Currently, there are no tele-ophthalmology programs that meet category 4 criteria
which would allow the replacement of a comprehensive in person assessment.
However, mature tele-ophthalmology programs for DR screening in the US (more
than 10 years old) already have a category 3 validation in which level of DR is
assessed, instead of the simpler dichotomous classification of category 1 and 2
programs.132
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Table 2.1 Validation categories for Diabetic Retinopathy telescreening programs
(American Telemedicine Association)

ETDRS= Early Treatment Diabetic Retinopathy
1 American Telemedicine Association (2011)
2 Telehealth methods for diabetic retinopathy and glaucoma. ARVO education course. May 4, 2013

Several tele-ophthalmology programs for DR screening have been launched among
different settings and target populations in Australia141, United Kingdom142, France
and United States143. For example, Australian models are focused on the rural
setting, where underserved communities get a screening examination 900 km away
from the specialized center.144 Alternatively, tele-ophthalmology is also being used
for inmate follow-up examinations in a Texas prison, saving ground transportation
times and minimizing security requirements.145 In North America, the Joslin Vision
Network (JVN) located in Boston (MA) is an example of a validated category 3
program, with the main objective of providing adequate eye care to US veterans
from the US Veteran’s Administration.143 The JVN program has also been
incorporated into the Phoenix Indian Medical Center, providing diabetic eye care for
Native Americans living in reservations.146
2.1.6 Concluding remarks
There are currently 347 million diabetics worldwide, from which 33% have signs of
DR. About 50% of diabetic patients seek eye examinations, whereas the remaining
50% are still at risk of blindness from DR.6 Unfortunately, Canada is not the
exception.78 According to a recent study conducted by Boucher and collaborators,
the rate of diabetic patients who are noncompliant to DR Canadian guidelines is 68%
in Quebec, Manitoba, Saskatchewan, Alberta and British Columbia. Moreover, 38%
of diabetic patients in the mentioned provinces have never had an eye
examination.147 Besides lack of awareness regarding diabetic eye complications,
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inaccessibility and difficulty of getting an appointment for screening is another main
reason for not getting a screening examination.138
Discrepancies in access to eye care are unlikely to subside in the future. As the
incidence of diabetes increases over 50%, the growth in the number of
ophthalmologists in North America is dismal (less than 2%).148 Consequently, an
increasing number of patients will require an eye care examination at least every
two years but even less eye specialists would be available to fulfill the demand for
eye care.106 Public health agencies will be unable to meet DR screening guidelines
relying exclusively on the traditional in-person examination.
2.2 Thesis rationale
As described previously, tele-ophthalmology is an emerging alternative for DR
monitoring, and is being explored in many geographic settings and across several
scenarios of in-place physician accessibility.114 Multiple studies have evaluated the
effectiveness of ongoing tele-ophthalmology programs by means of assessing
diagnostic accuracy estimates such as sensitivity, specificity and kappa values. The
methods and settings vary widely among studies; equipment specifications and cutoff criteria also differ according with program needs and available technology.
To date, only three reviews have attempted to systematically summarize the
effectiveness of screening programs for DR monitoring.81,127,149 The first quantitative
review was published in 1996, before the advent of tele-ophthalmology for DR
care.149 Later, Hutchinson and colleagues81 published a systematic review on
effectiveness of screening tests for DR which included 20 studies from 1987 to 1999.
They concluded that mydriatic retinal photography was the most effective strategy
for DR screening, even when compared to direct and indirect ophthalmoscopy.81
However, the authors did not perform a meta-analysis to estimate the diagnostic
accuracy of mydriatic retinal photography. In one recent review, Bragge et al
reported a meta-analysis of tests designed to detect presence or absence of DR.127
Using a hierarchical logistic regression approach, the overall sensitivity and
specificity was 82.5% (95%CI: 75.6-87.9) and 88.4% (95%CI: 84.5-91.4),
respectively.127 The study was limited only to studies that assessed the presence of
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any DR, whereas studies that evaluated the presence of referable retinopathy were
not quantitatively summarized. More importantly, methodological quality of
included studies was not assessed in this review.
Of note, none of these reviews were tailored to synthesize the evidence of teleophthalmology programs; on the contrary, they assessed all DR examination
strategies besides digital photography. Their scope included many screening
methods such as in-person examination (ophthalmoscopy), film camera, and
polaroid camera, which are not suitable for telemedicine.135 Hence, evidence of the
effectiveness of tele-ophthalmology programs for DR assessment has been
accumulating with no conclusive remarks. Furthermore, the use of pharmacologic
dilation and number of fields necessary to maximize the effectiveness of teleophthalmology screening still remains controversial.78,120 A systematic appraisal of
the literature considering the influence of mydriasis and number of fields on teleophthalmology programs is deemed necessary.
Equally important is the estimation of the economic impact of these programs and
the potential long-term benefits that may justify such investment. Several costeffectiveness studies have assessed the impact of screening programs for diabetic
retinopathy, from which a small subset focused on the economic evaluation of teleophthalmology technologies.94,145,150 A recent review of the economic evidence of
diabetic retinopathy151 included 13 cost-effectiveness studies that aimed to compare
key features of a DR screening program such as opportunistic screening as opposed
to systematic screening, screening frequency and incorporation of new effective (but
more costly) technologies for screening delivery. In general, studies have concluded
that the implementation of DR screening programs is cost-effective.152–154 However,
the clinical and economic effectiveness of tele-ophthalmology is still uncertain,
depending heavily on patient compliance, the workload for each retinal unit and the
scenario in which would be implemented (urban or non-urban).151,155,156
In Canada, well-developed tele-ophthalmology programs are operating in the
provinces of British Columbia, Vancouver and Quebec.78 With the goal of creating
new eye screening opportunities and promote regular attendance among diabetic
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patients, most programs have been implemented in remote settings that do not
have ophthalmologists on-site.157,158 Although not a substitute for comprehensive
eye examination, tele-ophthalmology act as a filter to identify and timely refer
patients in need for a specialist examination.135
Interestingly, no telescreening initiative has been taken to improve eye care
coverage for diabetic patients in a non-urban setting. Given the significant capital
investment that such an initiative would demand, an economic analysis would aid to
explore whether tele-ophthalmology is the best alternative for this specific context.
2.3

Thesis objectives

This thesis encompasses two different, yet highly dependent studies. The overall aim
is to determine the diagnostic accuracy of tele-ophthalmology strategies for diabetic
retinopathy screening, and to explore the cost-effectiveness of a pharmacy-based
tele-ophthalmology screening program for detection of diabetic retinopathy in nonurban Southern Ontario.
Objective 1 – Meta-analysis
a) To systematically identify, review and quantitatively synthesize the evidence
available pertaining to the diagnostic accuracy of tele-ophthalmology strategies for
DR screening in adults as compared to reference standards (7 field ETDRS
photographs or slit-lamp biomicroscopy).
b) To explore screening and study design factors that may influence the diagnostic
accuracy of tele-ophthalmology assessments such as pharmacologic dilation, number
of fields used, choice of reference standard and risk of patient selection bias.
Hypothesis Tele-ophthalmology programs meet the minimum effectiveness
requirements advised by the Canadian Ophthalmological Society (sensitivity over
80%, specificity between 90% and 95%).78
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Objective 2 – Cost-effectiveness analysis
To explore the cost-effectiveness of a pharmacy-based tele-ophthalmology program
compared to primary care consultation (ophthalmoscopy) for diabetic retinopathy
screening in Southern Ontario (Chatham-Kent region).
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3.1 Introduction
Diabetic retinopathy (DR) occurs as a microvascular complication that affects the
blood vessels in the retina of diabetic patients, leading to a high risk of blindness if
left untreated.1 Although treatments for DR are effective, economic, and available
within the public health system, it remains the leading cause of legal and functional
blindness for working-age adults in industrialized nations, representing 4.8% of cases
of vision loss worldwide.2,3 Early detection by regular screening for DR is a key factor
for its timely treatment, helping to prevent blindness and other impaired visual
conditions in diabetic individuals. 4 However, only 50% of patients with diabetes
mellitus (DM) follow the screening recommendations by the American Diabetes
Association.5
Within this context, tele-ophthalmology has emerged as a possible alternative that
facilitates compliance to evidence-based medicine, perhaps without geographic
constraints. It may improve consistency of healthcare in a cost-effective fashion.6–8
Tele-ophthalmology screening initiatives for DR have been tested and launched in
diverse settings as an attempt of providing specialized eye care to underserved
communities regardless geographic limitations, while also eliminating unnecessary
traveling for patients and specialists.9,10
Published studies have focused on the diagnostic accuracy of digital imaging
screening for DR in diverse settings for its use in store-and-forward teleophthalmology strategies.9,11 A literature review reported that sensitivity and
specificity of telescreening for detecting DR has been consistently high, and
concluded that this model appeared to be a suitable test for DR assessment.12 Other
reviews have addressed the diagnostic accuracy of diverse screening methods for
DR, including digital camera, film camera, direct examination and polaroid camera
assessments.13,14 Nevertheless, evidence on diagnostic accuracy of DR screening
focused on tele-ophthalmology strategies has not been critically synthesized in a
systematic review or meta-analysis.
Likewise, research and validation studies have also explored the influence of teleophthalmology components, namely, pharmacologic dilation, number of fields,
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automated grading and image compression to assess their impact on screening
diagnostic accuracy.15–17 However, there has been much discussion about the most
effective method for detecting DR in the telemedicine context, since current
evidence on this topic is contradictory and sometimes inconclusive.18,19 Bringing
these studies together and synthesizing their results, will promote a better
understanding of their clinical usefulness and influence on the diagnostic
performance of tele-ophthalmology programs.
Furthermore, the choice of gold standard for tele-ophthalmology validation studies
has been a subject of debate among specialists,20 who claim that the current
recommendation (standard 7 field ETDRS photographs) is impractical in rural
settings.6,21 Given the current gaps in the literature and the need of evidence
synthesis on this field, the present meta-analysis seeks the following objectives: 1) to
systematically identify, review and quantitatively synthesize the evidence available
pertaining to the diagnostic accuracy of tele-ophthalmology strategies for DR
screening in adults as compared to reference standards, and 2) to explore screening
and design factors that influence the diagnostic accuracy of tele-ophthalmology
assessments, namely pharmacologic dilation, number of fields used, choice of
reference standard, type of diabetes and risk of patient selection bias. Hence, we
hypothesized that tele-ophthalmology programs meet the minimum effectiveness
requirements advised by the Canadian Ophthalmological Society (sensitivity over
80%, specificity between 90% and 95%).22
3.2 Methods
We conducted and reported this meta-analysis in compliance with the Meta-analysis
of Observational Studies (MOOSE) recommendations (Appendix A) and Preferred
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines
(Appendix B).
3.2.1 Literature search
A structured search was conducted among six different databases (Medline,
EMBASE, CINAHL, BIOSIS, Web of Science, Cochrane Library) from January 1998 to
June 2012 (last update on January 2013), without language restrictions. Free text key
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words and medical subject headings were tailored to each of the electronic
databases, and included four main domains: diabetic retinopathy, diagnosis,
telemedicine and evaluation studies (see list of search terms for all databases in
Appendix C). A health information specialist (JC) contributed to the development of
the search strategy, in consultation with other team members including content
experts. Grey literature was addressed by manually searching electronic abstracts
and dissertations from The American Academy of Ophthalmology, the Association
for Research in Vision and Ophthalmology (ARVO) meetings. As a complementary
search, bibliographies of eligible studies and relevant systematic reviews retrieved in
the literature search were manually screened.23 All citations from each database
search were exported to the reference manager program EPPI version 4.3 (EPPI
Centre, Institute of Education, London, UK), for de-duplication and screening.
3.2.2 Eligibility criteria
Primary studies reporting sensitivity and specificity outcomes of a teleophthalmology strategy for DR diagnosis were included; we focused on those studies
that explicitly reported sensitivity and specificity estimates for the detection of any
retinopathy and/or referable retinopathy amongst adult patients with type 1 or type
2 diabetes. In the present review, any approach that promoted the screening of DR
by store-and-forward transmission of digital images, with the patient and the
ophthalmologist being in different geographical settings was considered a teleophthalmology strategy.6 The exclusion criteria were: (i) studies addressing pediatric
patients (< 18 years old), (ii) editorials, commentaries and opinion articles, (iii)
studies conducted in under-developed, developing or non-industrialized settings
(Latin America, Eastern Europe, Africa and most Asian countries), (iv) studies with a
reference standard different from 7 field ETDRS photographs or slit-lamp
biomicroscopy, v) studies with less than 20 fully-screened patients.
3.2.3 Article screening
The screening strategy involved a two-step process. First, titles and abstracts were
reviewed to identify potentially relevant articles. Next, full-text articles from
included citations were retrieved to closely assess inclusion and exclusion criteria.
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Two reviewers (AC and HS) screened citations and full-text articles in an independent
fashion, and Cohen’s kappa coefficients were used to examine inter-rater
agreement. We interpreted kappa values as follows: 0.40 to 0.59 reflect fair
agreement, 0.60 to 0.74 reflect good agreement, and ≥0.75 reflect excellent
agreement.24,25 Discrepancies were reconciled by discussion and any remaining
disagreements were solved through consultation with an experienced
ophthalmologist (WH), who assessed study eligibility. Articles published in language
other than English were initially addressed by a translator (AC for Spanish articles,
WG for French articles and independent translator for German articles) who
examined the title and abstract and determined the study relevance based on first
level screening questions.
3.2.4 Data extraction and quality assessment
A data extraction form was created and piloted with a subset of eligible studies.
Based on the experience gained in the pilot study, the final version of the data
extraction form (see appendix D) was used to collect the following information:
Number of fully-screened patients; race or ethnicity; % type II diabetes; %
prevalence; duration of diabetes; visual acuity; reference standard used; grading
guideline used; cut-off criteria; index technology (i.e type of camera, resolution);
field positioning and number of fields; pupil dilation; stereopsis; % unreadable
images; screen display resolution; image compression. The main outcomes of
interest were sensitivity and specificity, and outcomes in the form of true positives
(TP), false positives (FP), true negatives (TN) and false negatives (FN) if available. In
cases where these values were not available, we derived the numbers from the
sample size, DR prevalence and reported sensitivity and specificity.26 Data was
extracted by one reviewer (AC) and relevant predictor and outcome variables
(sensitivity, specificity, prevalence and 2x2 tables, if available) were confirmed
independently by a second reviewer (HS). Finally, a 2x2 table was constructed based
on the data extracted from the studies, defining the patient as the unit of analysis.
Primary authors were contacted in cases where studies provided insufficient
information to reconstruct the 2x2 tables.
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About half of the articles reported multiple results comparing different teleophthalmology protocols (e.g. more than one estimate of diagnostic accuracy per
primary study). To avoid clustering effect,27 we used a hierarchical approach to
choose one comparison per study: (1) protocols using pharmacologic dilation and
two or more field images per eye (2) protocols without pharmacologic dilation with
two or more field images per eye (3) protocols with pharmacologic dilation and a
single field image per eye (4) protocols without pharmacologic dilation and a single
field image per eye.
Quality assessment was performed using the revised QUADAS2 (Quality Assessment
of Diagnostic Accuracy Studies) criteria, which was adapted specifically for this
review, as suggested by current guidelines (Appendix E).28 No attempt was made to
assign a score to the QUADAS2 items, as this tool is not intended to generate a
summary quality score.29,30 Instead, risk of bias of each study was assessed as high,
low or unclear across the four QUADAS2 domains (patient selection, administration
of the index test, reference standard and patient flow).
3.2.5 Data synthesis and statistical analysis
Categories for analysis
As planned in the study protocol, we stratified the data into two categories
according to cut-off criteria. Category 1 included studies that aimed to detect any
diabetic retinopathy (at least one microaneurysm observed); category 2 included
studies that aimed to detect referable retinopathy (defined differently across
studies). Accuracy estimated at multiple test cut-offs was available in many studies;
in these cases, studies contributed one set of data points per category.
Meta-analysis
A meta-analysis was conducted separately for each category using a hierarchical
bivariate random effects model, proposed by Reitsma et al.31 Instead of using the
diagnostic odds ratio, the bivariate approach uses sensitivity and specificity pairs as
the starting point of the analysis, preserving the two-dimensional nature of the
data.32 Besides accounting for heterogeneity beyond chance, the bivariate model has
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the advantage of incorporating the negative correlation that may exist between
sensitivity and specificity, while accounting for variation within and between
studies.33,34 Summary sensitivity, specificity, positive/negative likelihood ratios
(LR+;LR -) and diagnostic odds ratio (DOR) were calculated for each category using
the bivariate method. Likelihood ratios are considered a useful measure for
clinicians. The LR- indicates how likely a negative test result is in a diseased person
compared to non-diseased person; conversely, LR+ estimates the frequency of a test
positive result in diseased compared to non-diseased individuals.35 The DOR is
calculated by LR+/LR- and it is interpreted as the odds of positivity in diseased versus
the odds of positivity in non-diseased. Values in DOR range from zero to infinity,
higher values indicate better discriminatory test performance.36
To graphically present the results, we plotted the hierarchical SROC (summary
receiver operating characteristic) graph for each category, which allows the
visualization of the test performance along different thresholds.37,38 This model
developed by Rutter and Gatsonis37 also accounts for variation within and between
studies, due to its hierarchical approach.39 Based on this model, we plotted the
individual and summary sensitivity and specificity pairs in an ROC graph where the y
axis indicates the index test’s sensitivity and the x axis equals 1-specificity. For
category 1 studies, we calculated the AUC (area under the curve) with the
corresponding 95% confidence region and 95% prediction region.40,41 If the AUC is
100% then the test discriminates perfectly between diseased and non-diseased
patients, whereas an AUC of 50% indicates poor diagnostic accuracy.42,43 Given that
category 2 studies use various thresholds of test positivity, the AUC was not
calculated.40
Heterogeneity
Initially, heterogeneity between studies was visually assessed through paired forest
plots. Cochran Q (X2 test) and I2 statistics were used to describe study dispersion
based on sensitivity and specificity estimates of included studies.44,45 Statistical
significance of Cochran Q test was assumed at a P value less than 0.10, due to the
power limitations of the test. I2 values of 25% 50% and 75% were considered of low,
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moderate and high inconsistency, respectively.44 Hierarchical ROC curve was also
used to assess heterogeneity likely due to threshold effect. With the hierarchical
SROC plot we were able to assess the proportion of heterogeneity likely due to
threshold effect. A shoulder-like curve where studies are tangent to the ROC curve
indicates that the observed variability between studies may be due to a threshold
effect.46,47
Finally, potential sources of heterogeneity were explored using subgroup analysis.48
We defined a priori the following characteristics as potential relevant covariates:
Pharmacologic dilation (“yes/mixed” or “no”), number of fields captured per eye
(“single” or “multiple fields”), reference standard used (“7 field ETDRS photographs”
or “slit-lamp biomicroscopy”), type of diabetes (“type 1” or “type 2” diabetes) and
risk of patient selection bias according to QUADAS2 criteria (“uncertain/high risk” or
“low risk”).49 Due to the exploratory nature of covariate analysis and to the small
number of studies per covariate, a meta-regression was not undertaken for the
above mentioned covariates.50
As a way to evaluate the possible association of up-to-date technologies on the
diagnostic performance of tele-ophthalmology programs, we executed a random
effects meta-regression of the DOR as the outcome and year of publication as the
independent variable.51 Thus, we considered the year of publication as an indicator
of improvement in both digital photography technologies and learning experience
associated with tele-ophthalmology. We performed a t-test to assess the null
hypothesis of no effect of year of publication (i.e recent technologies) on the DOR.52
A P value <0.05 was considered statistically significant.
Sensitivity analysis and publication bias
We repeated the analysis including only studies that fully met QUADAS2 criteria in all
four domains (patient selection, administration of index test, reference standard and
patient flow). As a concern for publication bias, we performed a funnel plot based on
DOR of each study (in logarithm scale) and their respective standard error. Finally,
we tested for symmetry and small-study effect using a linear regression approach as
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described by Egger et al.53–55 A P value less than 0.05 was considered statistically
significant for small study effect.56 This test was also used to numerically estimate
funnel plot asymmetry.
Statistical analysis was performed with Stata 12 (Stata Corp, Austin, TX USA). This
study was supported by a grant from the Ontario Innovation Fund. The founding
source had no role in the collection, analysis or interpretation of the data. Authors
have no industry funding source or industry conflict of interest to disclose.
3.3 Results
3.3.1 Search results and study characteristics
After removing duplicates, 1060 citations were initially screened from which 156
were shortlisted for full text assessment. A total of 22 articles met our criteria for
review;7,57–78 primary authors from two included studies74,77 were contacted for
further information from whom only one replied.74 Thus, one article was excluded
due to lack of sufficient information.77 Finally, one additional study was identified
through manual search of bibliographies of selected studies, for a total of 23
included studies for data collection and analysis. Inter-reviewer agreement for study
inclusion was excellent (Cohen’s k=0.83). The study identification and selection
process is described in Figure 3.1.
Characteristics of included studies are outlined in Table 3.1. The 23 studies included
a total of 5,541 fully screened patients, with a median study size of 149 (IQR 112).
Patients were mainly male (mean 54.2%), type II diabetic patients (mean 79%) of
median age 57 years (IQR 10.4 years). The median prevalence of any diabetic
retinopathy and referable retinopathy was 34.85% (IQR 15.2%), and 31% (IQR 41%)
respectively. The majority of tele-ophthalmologic protocols used a non-mydriatic
digital camera (69.6%), captured multiple field images per eye (52%) and used
pharmacologic mydriasis for pupil dilation (52%). Interestingly, only 44% of studies
used the recommended gold standard by the American Telehealth Association6 (7
field ETDRS photographs), whereas the remaining 56% used slit-lamp biomicroscopy
as the reference standard. Some studies evaluated the effectiveness of the teleophthalmology program at different thresholds, with and without pharmacologic
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dilation, and used different number of fields captured per eye, thus reporting
multiple diagnostic accuracy endpoints. The 23 final articles contributed to 31
sensitivity and specificity pairs in all.
3.3.2 Quality assessment
Studies varied in quality (Table 3.2, Figure 3.2). There were nine studies of low risk of
bias across all four domains of QUADAS2 criteria. Concerns about index technology
application were uniformly low for all studies in the quality assessment; similarly, all
studies adequately reported blinding of image readers. The two main issues arising
were related to the selection of patients and the analysis and/or interpretation
criteria of the index test. Patient selection was a concern in three studies,70,73,78
where patients were not enrolled on a consecutive or random basis. In addition,
three studies7,74,76 did not provide sufficient information to assess risk of patient
selection bias. Eight studies removed from the diagnostic accuracy analysis those
patients with uninterpretable results (ie. unreadable images), which may lead to
overoptimistic diagnostic accuracy outcomes.49 Similarly, some studies did not
report details about the data analysis, or whether they included or not the full
spectrum of patients.
Of note, less than 40% of included studies provided sufficient data about patient
race/ethnicity, visual acuity measures and image compression. Moreover, only 56%
of studies specified the type of diabetes. Thus, information regarding these
covariates was not summarized nor incorporated in the meta-analysis.
3.3.3 Meta-analysis
A wide range of results was observed among studies detecting any DR (category 1)
and referable DR (category 2). Figures 3.3 and 3.4 show individual accuracy
measures in a paired forest plot for each category. As anticipated in meta-analyses of
diagnostic accuracy studies,79 pooled results showed considerable heterogeneity
between included studies, which was statistically significant among both categories
(X2 P value <0.001). Inconsistency ranged from moderate to high, except for
sensitivity among studies detecting referable DR, where inconsistency was only
moderate (I2 71%; 95% CI: 57-86). The meta-analysis summary estimates were
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obtained using the hierarchical bivariate approach, which is the recommended
method for synthesis of diagnostic accuracy studies in presence of significant
heterogeneity.80 However, summary estimates should still be cautiously interpreted
given the marked heterogeneity amongst studies.
Synthesis of results by category
Summary statistics (sensitivity, specificity, DOR, LR(+), LR(-)) and their corresponding
95% confidence intervals for both categories are outlined in Table 3.3.
Category 1. Detection of any DR
This category included all studies that aimed to detect any DR (at least one microaneurysm or worse), which involved 16 studies for a total 3,167 fully screened
patients. After pooling the sensitivity and specificity of single studies using the
bivariate method, we obtained a combined sensitivity of 0.89 (95% CI: 0.81-0.93) and
combined specificity of 0.94 (95% CI: 0.89-0.96). As expected from pooling studies
with identical cut-off criteria, the proportion of heterogeneity likely due to threshold
effect was zero.
The accuracy of tele-ophthalmology for detecting any DR is graphically shown using
the hierarchical ROC curve that illustrates the summary point and the individual
study datapoints (Figure 3.5a). Using this approach, we found an AUC of 0.97 (95%
CI: 0.95-0.98) and a DOR of 113 (95% CI: 51-248). Although 60% of studies are
located towards the upper left of the graph indicating good test performance, the
presence of outliers influences the 95% prediction ellipse downwards.
Category 2. Detection of referable retinopathy
In this category, all studies that aimed to detect “referable DR” were included. Thus
we identified 15 studies, including 3,794 fully screened patients. The overall
sensitivity and specificity was 0.91 (95% CI: 0.87-0.94) and 0.92 (95% CI: 0.88-0.95),
respectively. According to the hierarchical bivariate model analysis, the proportion of
heterogeneity likely due to threshold effect was 0.13. However, this category
incorporates different thresholds which challenge the interpretation of a single
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paired estimate provided by the bivariate method, as it indicates the performance of
an unknown average threshold. Moreover, the prevalence of referable DR was
widely spread among studies (prevalence range: 5% -77%; IQR 41%). Thus, it is more
adequate to base the analysis on the hierarchical SROC plot that allows assessing the
performance of the test taking all thresholds into account, and visualize individual
study results (Figure 3.5b).81 The distribution of the studies in the plot shows a
greater variability in specificity rather than sensitivity.
Subgroup analysis
Results from subgroup analysis are presented in Table 3.4. Due to the limited
number of studies available in category 1 (detection of any DR), covariance analysis
of studies that used a single field per eye was not possible. Otherwise, all remaining
a priori subgroup analyses were conducted.
Overall, specificity values remained constant across subgroups; sensitivity outcomes
varied considerably, especially among studies that aimed to detect any DR (category
1). For example, category 1 studies that used 7 field ETDRS fundus photographs as
the reference standard showed higher sensitivity (0.96; 95%CI: 0.93-1.00) compared
to their counterparts that chose slit-lamp biomicroscopy for gold standard
(0.84;95%CI: 0.76-0.91). Moreover, studies that did not use pharmacologic dilation
had a lower sensitivity compared to the overall calculated for the detection of any
DR (0.84 versus 0.89). However, such differences in sensitivity among the above
mentioned subgroups did not hold for category 2 studies (detection of referable DR).
Heterogeneity did not significantly improve across subgroups. Nevertheless, studies
that used 7 field ETDRS photographs as the reference standard were less
inconsistent compared to the overall estimate.
Meta-regression results for each category are represented in the bubble plots
(Figure 3.6). The magnitude of each circle is proportional to the inverse of the
within-study variance of the corresponding study. Only category 1 studies (detection
of any DR) showed a statistically significant association between year of publication
and increased DOR (p-value 0.002).
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Sensitivity analyses and publication bias
Publication bias was visually assessed by an individual funnel plot per category
(Figure 3.7). The funnel plot is noticeably asymmetric among both categories, with
missing studies at the bottom left of the graph indicating potential publication bias
towards studies with positive results. For studies that detect any DR, Egger’s test for
small study effects was non-significant (p-value 0.072), discarding the influence of
small study effects in the asymmetry of the funnel plot. In contrast, evidence of small
study effects was found among studies detecting referable retinopathy (p-value
0.004).
When sensitivity analyses were performed for category 1 studies, summary
sensitivity endpoints of individual studies were significantly less heterogeneous
when studies with high risk of bias were excluded (Cochrane Q 8.79; P value 0.19)
(see Appendix F). Diagnostic accuracy and heterogeneity remained constant in
category 2 studies (detection of referable retinopathy).
3.4 Discussion
3.4.1 Principal findings
Considering the quantitative summary results from the present review, it appears
that tele-ophthalmology approaches meet the requested targets for an effective
diabetic retinopathy screening program, as recommended by the Canadian
Ophthalmological Society (sensitivity >0.80, specificity >0.90).22,82 In category 1,
which included studies with a common threshold value (detection of any DR),
summary estimates showed a satisfactory diagnostic performance (sensitivity 0.89,
specificity 0.94). In line with these findings, category 2 studies also showed high
diagnostic performance for the detection of referable retinopathy (sensitivity 0.91,
specificity 0.92). Although these are satisfactory outcomes, substantial heterogeneity
was observed in both categories (Cochrane test P <0.001), limiting both the clinical
interpretation and applicability of these summary estimates. Moreover, studies in
category 2 do not share a common cut-off value, as studies reported different
threshold definitions for the detection of referable DR. In such situation, a summary
estimate calculated from the bivariate model represents an average operating point
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for an average unknown threshold, which has no clinical significance.80 The
interpretation of the hierarchical SROC plot for this category (Figure 3.5) has greater
importance as it adequately represents study information from different
thresholds.81
Exploration of potential sources of heterogeneity is of crucial importance in
systematic reviews.48,49 Thus, we performed subgroup analyses to identify potential
sources of variability previously suggested in the literature. This approach also
provided the appropriate framework to explore the influence of choice of reference
standard on the diagnostic performance of tele-ophthalmology programs. Among
category 2, we noted that studies using a single image approach had an inferior
diagnostic performance (sensitivity 0.82; specificity 0.86) compared to the overall
analysis (sensitivity 0.91;specificity 0.92) These findings resonate with previous
studies that used a single field photograph per eye for DR assessment and reported
sensitivity values as low as 0.71.83 With a single field photograph, pathologies at the
retinal periphery may be missed, which in turn influences the rate of false negatives
and affects the sensitivity of the screening test.71,72
We observed further differences in summary sensitivity endpoints among category 1
subgroups (Table 3.4). First, we observed that the choice of gold standard had some
impact on the sensitivity outcomes of the index test. Studies using 7 field ETDRS
photographs as the gold standard had greater sensitivity (0.96; 95%CI: 0.93-1.00)
compared to studies that chose ophthalmoscopy (0.84; 95%CI:0.76-0.91). Our finding
is of special importance, since 54% of included studies reported the use of
ophthalmoscopy as the reference standard for the evaluation of DR screening
programs, instead of the recommended gold standard by the American Telehealth
Association (7 field ETDRS photographs).6 Based on our results, researchers may take
into account that the choice of ophthalmoscopy over 7 field ETDRS photographs as
the gold standard may negatively affect the sensitivity performance of the index test
if it aims to detect early forms of DR.
Second, meta-regression analysis found that recently published studies were
associated with greater diagnostic accuracy for the detection of any DR. Such a trend
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could be related to the continuous improvement of digital technologies that
facilitate the identification of subtle manifestations of DR such as micro-aneurysms.
Finally in the sensitivity analysis, we found that poor methodological quality also
accounts for some observed heterogeneity in pooled sensitivity results among
category 1 studies. After excluding studies with risk of bias as graded using QUADAS2
criteria, we found that heterogeneity of sensitivity estimates was no longer
significant (Cochran Q 8.79; P value 0.19), and inconsistency among studies was
reduced to 31.7% (moderate inconsistency). However, such difference was observed
only in sensitivity estimates of studies in category 1 and did not hold for studies in
category 2 (referable retinopathy).
It is important to note that in all screening programs there is certain degree of harm.
In the case of tele-ophthalmology, the potential harm related to the screening
process itself is generally innocuous. If dilation drops are used, there is a small risk
for temporal development of open angle glaucoma. However, the risk of this adverse
event is very low, 1 in 20,000 cases.87
Adverse effects of screening are also related to the occurrence of false positive or
false negative results. Patients with false positive tests undergo additional
unnecessary examinations such as ocular coherence tomography or fluorescein
angiography.12 Besides the psychological distress resulting from positive results,
confirmatory tests do not represent significant harm. Allergic reactions may occur
due to administration of sodium fluorescein during fluorescein angiography,
although serious complications are rare.88 False negative tests may translate to
missed opportunities for preventing severe vision loss.
According to our results, tele-ophthalmology screening for DR can accomplish
sensitivity and specificity estimates over 80% and 95%, respectively. Such diagnostic
performance is considered sufficient for supporting the early diagnosis of DR through
screening programs.88

62

3.4.2 Strengths and limitations
To our knowledge, this is the first meta-analysis that evaluates and summarizes the
diagnostic performance of tele-ophthalmology screening for the assessment of DR.
This meta-analysis has a number of strengths. We performed a robust literature
search in collaboration with an information specialist, which included a
comprehensive search of major scientific databases and reference lists of reviews
and articles. In addition, we selected studies according to strict inclusion criteria
assessed by two reviewers; we also assessed methodological quality of studies and
used two suitable statistical models for diagnostic meta-analysis in the presence of
heterogeneity and different thresholds.
There are some limitations to be considered when interpreting the study results. We
observed considerable heterogeneity among both study categories (Cochran Q P
value <0.001), which could be explained in part by threshold effect (for category 2
studies) and poor methodological quality of some studies (for category 1 studies).
According to our exploratory subgroup analysis, differences in the selection of
reference standard and number of fields taken per eye may also contribute for the
heterogeneity observed. However, subgroup analyses did not fully explained the
variability found, as results remained heterogeneous even after stratifying by predefined covariates. Thus, in presence of substantial heterogeneity summary results
should be cautiously interpreted. Evidence of publication bias is also a concern when
interpreting summary results, as it might have an impact on study conclusions
leading to overoptimistic results. However, it has been debated that in the context of
reviews of diagnostic accuracy studies applying such tests for funnel plot asymmetry
often lead to a high type two error rate (publication bias is incorrectly indicated by
the test).84
This meta-analysis was also limited by lack of information provided in primary
studies. We observed that almost 45% of authors did not report important
population characteristics such as ethnicity, type of diabetes and diabetes duration.
Reporting of visual acuity was almost non-existent, as only three authors reported
visual acuity of their study population.64,69,70 Lack of information on visual acuity
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precludes any estimation of relationships between diagnostic accuracy and
functional status. Similarly, some index test characteristics were also poorly
reported. For example, 65% of studies did not mention the digital image resolution
and 80% of studies did not provide information about image compression or image
formatting. These are index technology characteristics of important relevance in
image quality, which may influence the correct identification of DR cases.85,86
Because of the limited information provided on population and digital image
characteristics, future reporting of these research studies should give greater
attention to provide more complete information about population characteristics,
and detailed description of index technology devices. This will allow future reviews
to account for these important sources of variability.
In conclusion, this systematic review with meta-analysis suggests that teleophthalmology tests used to assess any DR and referable DR yield satisfactory
sensitivity and high specificity. Of note, diagnostic accuracy estimates amongst
individual studies were highly variable, compromising the clinical significance of the
meta-analysis results which in turn should be cautiously interpreted.
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Table 3.1. Characteristics of primary studies included in the Meta-analysis

Citation

Country

N (fullyscreened)

Ahmed J., et al (2006)

United States

156

Mean
age
(years)
60

Aptel F., et al (2008)

France

79

52.4

Baeza M., et al
(2004)+

Spain

188

68.5

34.7%

100%

Baeza M., et al
(2009)+

Spain

216

68.5

43.7%

90%

Boucher MC., et al
(2003)
Chun DW., et al
(2007)
Hansen AB., et al
(2004)
Herbert HM., et al
(2003)

Male (%)
54.5%
0.89
(men/women)

Type II
Cut-off
diabetes Gold standard
criteria
(%)
97.9% Ophthalmoscopy Any DR
62%

Canada

79

59.9

49%

NR

United States

120

NR

50.8%

NR

Denmark

83

47

60.2%

27.0%

United Kingdom

145

NR

NR

73%

DR
prevalence
15.8%*

Ophthalmoscopy Any DR

25.3%

Any DR
Ophthalmoscopy Referable
DR
Any DR
7 field ETDRS
Referable
photographs
DR
Any DR
7 field ETDRS
Referable
photographs
DR

41.25%

Ophthalmoscopy Any DR

32.5%*

7 field ETDRS
photographs

Referable
DR

Ophthalmoscopy Any DR

Li HK., et al (2010)

United States

76

59.4

37.6%

NR

7 field ETDRS
photographs

Lin DY., et al (2002)

United States

197

NR

58.0%

NR

7 field ETDRS

Any DR
Referable
DR
Referable

14.3%
37.2%*
14.3%
63.30%
53.10%

74.7%*
26.0%
82.9%
77.6%*
36.6%*

76

photographs
Lopez-Bastida J., et al
(2007)

Spain

651

50.8

51.8%

NR

Canada

100

54.6

31.0%

Massin P., et al (2003)

France

74

52

62.2%

Molina-Fernandez E.,
et al (2008)

Spain

49

65.4

NR
57%

65%

100%

Murgatroyd H., et al
(2004)

United States

293

63
(median)

Olson JA., et al (2003)

United Kingdom

550

56.5

65%

82.1%

Australia

149

68.5

57%

NR

United States

152

NR

NR

NR

Canada

102

59.9

65.7%

86.3%

United Kingdom

1542

65

NR

NR

Robbins AS., et al
(2001)
Rudnisky CJ., et al
(2007)
Scanlon PH., et al
(2003)
Schiffman RM., et al
(2005)

United States

94

57

41%

Ophthalmoscopy Any DR

Any DR
NR
Ophthalmoscopy Referable
DR
7 field ETDRS Referable
85.13%
photographs
DR

Maberley D., et al
(2002)

Phiri R., et al (2006)

DR

NR

42.5%
40.0%
31.0%*
12.9%*

Ophthalmoscopy Any DR

28.7%

Any DR
Ophthalmoscopy Referable
DR
Any DR
Ophthalmoscopy Referable
DR
7 field ETDRS Referable
photographs
DR

37.8%

Ophthalmoscopy Any DR
7 field ETDRS
photographs

Referable
DR
Referable
Ophthalmoscopy
DR
Any DR
7 field ETDRS
Referable
photographs
DR

4.70%
27.27%
9.9%
48.6%*
18.0%
4.9%
11.6%
76.10%
67.02%*

77

Ting DS., et al (2012)
Vujosevic S., et al
(2009)

Australia

136

53.9

NR

71%

Italy

55

57.1

60%

67.3%

* Prevalence calculated from reported 2x2 tables DR= Diabetic retinopathy NR= Not reported
Ophthalmoscopy examination included slit-lamp biomicroscopy performed by experienced ophthalmologist or retina specialist
+Studies may contain overlapping patient populations

Ophthalmoscopy Any DR
7 field ETDRS Referable
photographs
DR

31.3%
51.4%
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Table 3.2 QUADAS2 assessment results
PATIENT
SELECTION

INDEX
TEST

REFERENCE
STANDARD

FLOW AND
TIMING

Ahmed J., et al (2006)

Low

Low

Low

High

Aptel F., et al (2008)

Low

High

Low

Low

Baeza M., et al (2004)

Low

Low

Low

Low

Baeza M., et al (2009)

Low

Low

Low

Low

Boucher MC., et al (2003)

Low

Low

Low

Low

Chun DW., et al (2007)

Low

Low

Low

High

Hansen AB., et al (2004)

High

Low

Low

Low

Herbert HM., et al (2003)

Unclear

Low

Low

Low

Li HK., et al (2010)

High

Low

Low

Low

Lin DY., et al (2002)

Low

Low

Low

Unclear

Lopez-Bastida J., et al (2007)

Low

Low

Low

Low

Maberley D., et al (2002)

Low

Low

Low

Low

Massin P., et al (2003)

Low

Low

Low

Unclear

Molina-Fernandez E., et al (2008)

Low

Low

Low

Low

Citation, year

Murgatroyd H., et al (2004)

Low

Low

Low

High

Unclear

Low

Low

Low

Phiri R., et al (2006)

Low

Low

Low

Low

Robbins AS., et al (2001)

Low

Unclear

Low

High

Rudnisky CJ., et al (2007)

Low

Low

Low

Low

Scanlon PH., et al (2003)

Low

Low

Low

Unclear

Schiffman RM., et al (2005)

High

Low

Low

Low

Ting DS., et al (2012)

Low

Low

Low

Low

Unclear

Unclear

Low

Low

Olson JA., et al (2003)

Vujosevic S., et al (2009)

QUADAS-2
Domain
Flow and Timing

Low

Reference Standard

Unclear
High

Index Test

Patient Selection
0%

50%

100%

Proportion of studies with risk of bias (high, low, unclear)

Figure 3.2 QUADAS2 assessment (risk of bias by domain)
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StudyId

SENSITIVITY (95% CI)

StudyId

SPECIFICITY (95% CI)

Baeza DM et al., 2009

0.85 [0.75 - 0.92]

Baeza DM et al., 2009

0.94 [0.89 - 0.97]

Schiffman RM et al., 2005

0.99 [0.92 - 1.00]

Schiffman RM et al., 2005

1.00 [0.85 - 1.00]

Li HK et al., 2010

0.98 [0.91 - 1.00]

Li HK et al., 2010

0.92 [0.64 - 1.00]

Boucher MC et al., 2003

0.98 [0.89 - 1.00]

Boucher MC et al., 2003

0.81 [0.64 - 0.93]

Herbert HM et al., 2003

0.38 [0.22 - 0.56]

Herbert HM et al., 2003

0.95 [0.90 - 0.99]

Aptel F et al., 2008

0.95 [0.75 - 1.00]

Aptel F et al., 2008

0.98 [0.91 - 1.00]

Ahmed J et al., 2006

0.84 [0.64 - 0.95]

Ahmed J et al., 2006

0.86 [0.79 - 0.92]

Robbins AS et al., 2001

0.75 [0.55 - 0.89]

Robbins AS et al., 2001

0.85 [0.77 - 0.91]

Baeza DM et al., 2004

0.88 [0.79 - 0.95]

Baeza DM et al., 2004

0.95 [0.89 - 0.98]

Olson JA et al., 2002

0.83 [0.76 - 0.89]

Olson JA et al., 2002

0.79 [0.75 - 0.83]

Lopez-Bastida et al., 2007

0.92 [0.88 - 0.95]

Lopez-Bastida et al., 2007

0.96 [0.93 - 0.98]

Maberley D et al., 2002

0.85 [0.70 - 0.94]

Maberley D et al., 2002

0.80 [0.68 - 0.89]

Ting SW et al., 2011

0.93 [0.81 - 0.99]

Ting SW et al., 2011

0.98 [0.93 - 1.00]

Murgatroyd H., et al, 2004

0.90 [0.84 - 0.95]

Murgatroyd H., et al, 2004

0.90 [0.86 - 0.94]

Molina-Fernandez et al., 2005

0.86 [0.57 - 0.98]

Molina-Fernandez et al., 2005

0.97 [0.85 - 1.00]

Chun MDW et al., 2007

0.59 [0.42 - 0.74]

Chun MDW et al., 2007

1.00 [0.96 - 1.00]

0.89[0.81 - 0.93]

COMBINED

COMBINED

0.94[0.89 - 0.96]

Q =154.39, df = 15.00, p = 0.00

Q =183.44, df = 15.00, p = 0.00

I2 = 90.28 [86.64 - 93.93]
0.2

I2 = 91.82 [88.91 - 94.74]

1.0
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SENSITIVITY

1.0
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Figure 3.3. Paired forest plot of meta analyses of studies included in category 1
(detection of any DR)
Author , year / citation

SENSITIVITY (95% CI)

Author , year / citation

SPECIFICITY (95% CI)

Li HK et al., 2010/76

0.97 [0.88 - 1.00]

Li HK et al., 2010/76

0.94 [0.71 - 1.00]

Vujosevic S et al., 2009/55

0.81 [0.62 - 0.94]

Vujosevic S et al., 2009/55

0.93 [0.76 - 0.99]

Baeza DM et al., 2009/216

0.94 [0.79 - 0.99]

Baeza DM et al., 2009/216

0.98 [0.95 - 0.99]

Rudnisky CJ et al., 2007/102

0.80 [0.28 - 0.99]

Rudnisky CJ et al., 2007/102

0.99 [0.94 - 1.00]

Phiri R et al., 2006/149

0.86 [0.76 - 0.93]

Phiri R et al., 2006/149

0.71 [0.60 - 0.81]

Schiffman RM et al., 2005/94

0.95 [0.87 - 0.99]

Schiffman RM et al., 2005/94

0.81 [0.63 - 0.93]

Baeza DM et al., 2004/188

0.89 [0.71 - 0.98]

Baeza DM et al., 2004/188

0.99 [0.96 - 1.00]

Murgatroyd H et al., 2004/293

0.79 [0.49 - 0.95]

Murgatroyd H et al., 2004/293

0.95 [0.92 - 0.97]

Hansen AB et al., 2004/83

0.95 [0.87 - 0.99]

Hansen AB et al., 2004/83

0.95 [0.76 - 1.00]

Boucher MC et al., 2003/79

0.97 [0.85 - 1.00]

Boucher MC et al., 2003/79

0.95 [0.85 - 0.99]

Massin P et al., 2003/74

1.00 [0.69 - 1.00]

Massin P et al., 2003/74

0.85 [0.74 - 0.92]

Scanlon PH et al., 2003/1542

0.88 [0.82 - 0.92]

Scanlon PH et al., 2003/1542

0.86 [0.84 - 0.88]

Lin DL et al., 2002/197

0.78 [0.66 - 0.87]

Lin DL et al., 2002/197

0.86 [0.79 - 0.92]

Olson JA et al., 2002/545

0.93 [0.82 - 0.98]

Olson JA et al., 2002/545

0.87 [0.84 - 0.90]

Maberley D et al., 2002/100

0.91 [0.75 - 0.98]

Maberley D et al., 2002/100

0.82 [0.71 - 0.91]

0.91[0.87 - 0.94]

COMBINED

COMBINED

0.92[0.88 - 0.95]

Q = 49.41, df = 14.00, p = 0.00

Q =170.06, df = 14.00, p = 0.00

I2 = 71.67 [56.91 - 86.43]
0.3

1.0
SENSITIVITY

I2 = 91.77 [88.73 - 94.81]
0.3

1.0
SPECIFICITY

Figure 3.4. Paired forest plot of meta-analyses of studies included in category 2
(detection of referable DR)
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Figure 5b. Referable Diabetic Retinopathy
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Figure 5a. Any diabetic retinopathy
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Figure 3.5 Hierarchical SROC (summary receiver operator characteristic) plots for
detection of any diabetic retinopathy (5a), and detection of referable diabetic
retinopathy (5b)
Table 3.3 Meta-analysis summary results per category (detection of any diabetic retinopathy and
detection of referable diabetic retinopathy)
Category
Category
1
(n=16)
Category
2
(n=15)

Cut-off

Heterogeneity
Inconsistency
Cochran Q
2
2
(I ) [95% CI] (Chi P value)

Sensitivity
[95% CI]

Diagnostic performance
Specificity
DOR
LR +
[95% CI]
[95%CI] [95% CI]

LR [95% CI]

Any DR

96.95%
[94-99]

56.3
(P <0.001)

0.89
[0.81-0.93]

0.94
113
13.8
0.12
[0.89-0.96] [51-249] [8.3-22.7] [0.07-0.21]

Referable
DR

81.95%
[60-100]

10.7
(P 0.002)

0.91
[0.87-0.94]

0.92
121
12.0
0.10
[0.88-0.95] [58-253] [7.1-20.1] [0.07-0.14]
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Table 3.4. Subgroup analyses of potentially relevant covariates to explore heterogeneity
Number
of
studies

Heterogeneity

Sensitivity

Specificity

Inconsistency
2
(I )

Cochrane Q
2
(Chi )

(95% CI)

(95% CI)

97%
(94-99)

56.3
(<0.001)

0.89
(0.81-0.93)

0.94
(0.89-0.96)

92%
(82-100)
94%
(88-99)

22.3
(<0.001)
30.4
(<0.001)

0.91
(0.82-0.95)
0.84 (0.660.93)

0.95
(0.92-0.97)
0.91
(0.68-0.98)

56%
(0-100)
-

4.5
(0.052)
-

0.91 (0.88-0.95)
-

0.93
(0.90-0.97)
-

72%
(37-100)
97%
(93-99)

6.99
(0.015)
50.65
(<0.001)

0.96
(0.93-1.00)
0.84
(0.76-0.91)

0.93
(0.86-1.00)
0.94
(0.90-0.97)

90%
(79-100)
95%
(90-99)

19.3
(<0.001)
38.3
(<0.001)

0.88
(0.82-0.95)
0.92
(0.57-0.99)

0.94
(0.89-0.97)
0.94
(0.78-0.98)

10.7

0.91

0.92

Detection of any diabetic retinopathy
Overall analysis
Pharmacologic dilation

16

Yes/mixed

11

No

4

Number of fields
Multiple
Single*

13
3

Gold standard
7-field ETDRS photographs
Slit-lamp biomicroscopy
Risk of patient selection bias
Low risk

4
12

12

4
Uncertain/High risk
Detection of referable diabetic retinopathy
Overall analysis
15

82%

82

(60-100)

(0.002)

(0.87-0.94)

(0.88-0.95)

74%
(42-100)
60%
(10-100)

7.6
(0.011)
5.0
(0.041)

0.92
(0.88-0.95)
0.87
(0.82-0.93)

0.95
(0.88-0.98)
0.89
(0.82-0.96)

72%
(38-100)
79%
(95-100)

7.2
(0.014)
9.5
(0.004)

0.93
(0.89-0.95)
0.82
(0.74-0.88)

0.94
(0.89-0.97)
0.86
(0.75-0.93)

69%
(29-100)
77%
(47-100)

6.29
(0.022)
8.23
(0.008)

0.92
(0.88-0.95)
0.89
(0.84-0.95)

0.93
(0.88-0.97)
0.92
(0.86-0.98)

84%
12.2
0.88
(65-100)
(0.001)
(0.84-0.92)
0%
0.004
0.94
Uncertain/High risk
5
(0-100)
(0.499)
(0.90-0.96)
* Covariate analysis could not be conducted for this subgroup given the small number of studies (n <4)

0.93
(0.87-0.97)
0.88
(0.85-0.90)

Pharmacologic dilation
Yes/mixed

8

no

7

Multiple

11

Single

4

Number of fields

Gold standard
7-field ETDRS photographs

10

Slit-lamp biomicroscopy
Risk of patient selection bias

5

Low risk

10
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B. Category 2 studies (Referable DR)
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Figure 3.6 Meta-regression of log diagnostic odds ratio (DOR) on year of study
(independent variable) for A. Detection of any diabetic retinopathy and B. Detection of
referable diabetic retinopathy

A. Category 1- Any Diabetic Retinopathy

B. Category 2- Referable Diabetic
Retinopathy

Egger’s test p-value 0.072

Egger’s test p-value 0.004

Figure 3.7 Funnel plot of standard error of log diagnostic odds ratio (logDOR) by logDOR
for each study category to illustrate possible publication bias. Egger’s p-value < 0.05
indicates presence of small study effects
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4.1 Introduction
Diabetic retinopathy (DR) is a sight threatening complication in patients with diabetes
mellitus, and is usually asymptomatic in early stages1–3. According to recent
investigations, 2.5% of diabetic patients worldwide suffer severe vision loss derived
from DR, being this the leading cause of blindness among working-aged individuals.4,5
Regular eye examination is fundamental to detect DR progression and to promote
timely therapeutic interventions.6 Laser photocoagulation for example, is an effective
treatment for DR with 52% of patients experiencing reduction of severe vision loss if
they receive treatment after timely diagnosis of sight-threatening DR.7,8
Unfortunately, less than 50% of diabetic patients follow the eye examination guidelines
by the American Academy of Ophthalmology9, resulting in lost opportunities to prevent
severe vision loss by means of adequate treatment delivery.5,10,11 Besides nonmodifiable factors, limited availability of eye care specialists, travelling difficulties and
time constraints are also well-known reasons for non-adherence in non-urban areas.12–
15

Within this context, pharmacy-based tele-ophthalmology has emerged as a possible
alternative that may facilitate compliance with evidence-based recommendations and
reduce barriers to specialized eye care.16–18 In this program, retinal digital images are
captured in a local pharmacy and securely transmitted electronically to a specialized
reading centre, where photographs are graded by an eye specialist.19 Patients with signs
of DR can then be referred to an eye-care professional for comprehensive assessment.20
Thus, the workload of routine eye examination is transferred to other (presumably less
expensive) settings, optimizing the use of specialized eye-care services. In addition, this
approach eliminates unnecessary traveling for patients and eye care professionals, and
it may improve the consistency of community-based eye care delivery without
geographic constraints.17,21
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Cost-effectiveness of new technologies should be explored before implementation in
specific settings in order to facilitate estimation of the eventual costs of introducing new
technologies, as well as their potential benefits compared with competing
alternatives.22 Amongst cost-effectiveness studies conducted in the DR screening arena,
few have evaluated tele-ophthalmology as an alternative for in-person examination.23–27
Thus, the objective of this study was to estimate the cost-effectiveness of mobile teleophthalmology screening compared to primary care examination for the diabetic
population residing in non-urban areas of Southwestern Ontario (Canada). Our primary
interest was to assess the additional cost per case detected of any diabetic retinopathy
with pharmacy-based tele-ophthalmology on an annual basis from the health system
perspective. Unlike previous studies, we consider a more realistic scenario in which the
tele-ophthalmology program would not entirely replace in-person examination, while
also accounting for the effects of performing a dilated or non-dilated examination with
tele-ophthalmology.
4.2 Methods
4.2.1 Study setting
The economic analysis was designed for the South-western Ontario context, specifically
non-urban areas at the Erie-St. Clair Local Health Integration Network (LHIN).28 Such
non-urban areas have limited specialized eye-care and diabetic care, in which a
pharmacy-based tele-ophthalmology system may be of benefit, as it would help
reaching diabetic individuals who otherwise would not get an eye examination.29 As of
2011, the census subdivision contemplated in this study (Chatham-Kent) reported a
total of 103,671 habitants (population density of 14.2 people per km2), from which
10,354 are type I or type II diabetic persons over 20 years old.30,31 An explicitly urban
model (ie Toronto) was not chosen based on the assumption that in-person exams
would be relatively easy to access in this setting. An explicitly rural model (Canada’s far
north) was not chosen since tele-ophthalmology may be the only alternative in such
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locations. However, there is true equipoise in understanding the cost-effectiveness of
this program in a context such as the Erie-St Clair LHIN.
4.2.2 Decision-tree model and study interventions
A decision-tree was elaborated using TreeAge Pro Suite 2013 (TreeAge Software, Inc,
Williamstown, Massachusetts), to compare primary care examination (comparator
program) versus pharmacy-based tele-ophthalmology (intervention program). 32 A
simplified diagram of the decision-tree is provided in Figure 4.1 (for the full model, refer
to appendix G). In the analytical framework, we assumed that the pharmacy-based teleophthalmology program coexisted along with the reference program, increasing the
volume of DR examinations (Figure 4.1, arm 2) but did not entirely replace in-person
examination. This assumption aligns to the purpose of the tele-ophthalmology program
to complement existing eye-care services.
The model was tailored for a mixed cohort of adults with type I or type II diabetes. The
outcome of interest was the detection of any diabetic retinopathy, manifested by at
least one micro-aneurysm (ETDRS ≥ 20).33 This health outcome was chosen based on the
goal of identifying both early and advanced stages of DR, which would promote an
appropriate follow-up or timely treatment, if necessary.
Our interest focused on the potential ability of pharmacy-based tele-ophthalmology to
strengthen diabetic retinopathy screening coverage at a reasonable cost. Thus, our
analysis was restricted to the correct detection of DR cases, as opposed to incorporating
treatment effects and disease progression into the model. A heath care system
perspective was adopted, where consequences and direct costs pertaining to each
program were included based on a 12-month time frame.
Intervention: Pharmacy-based tele-ophthalmology
The economic model was designed for the evaluation of a category 1 teleophthalmology screening program, used to identify patients with no (or minimal) DR
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and patients with more than minimal DR.16 We considered the introduction of a parttime mobile retinal unit, operating on a rotational basis among regional pharmacies at
the main municipalities of Chatham-Kent. In this model, clinical history and 45 degree
digital photographs were taken from each eye by an ophthalmic photographer and
pharmacologic dilation with tropicamide or phenilephrine was optional. Readable digital
images were sent via electronic communications to the reading center at St. Joseph’s
hospital in London (ON) for assessment by a retina specialist. Patients with positive
findings were referred to a retina specialist for a diagnostic confirmation with
angiography and optical coherence tomography. Similarly, patients with unclear fundus
photographs were referred to in-person examination with the retina specialist for
further assessment.
Comparator: In-person examination (primary care)
The primary care screening was defined as a dilated fundus examination performed by a
primary care eye specialist (either an optometrist or ophthalmologist). Patients with
positive results were referred to a retina specialist for a comprehensive eye examination
with angiography and optical coherence tomography.
4.2.3 Identification and calculation of model probabilities
Probabilities used in the base-case model are shown in Table 4.1. Prevalence of any DR
(22.5%) was calculated using public reports by the Public Health Agency of Canada and
the National Coalition for Vision Health.34,35 Screening rate with the reference program
in Arm 1 (P(ref)) was considered to be identical to the eye examination rate after
diagnosis of diabetes in Ontario (51.1%).36 After the introduction of the new screening
intervention (appendix G, Arm 2), the patient had two screening alternatives (in-person
examination or telescreening) and would choose according to preference for one or the
other. The option of no screening was also included in both arms of the model. Hence,
to calculate the screening rate of tele-ophthalmology examinations (P(tele)), we used the
following formula that considered the increased screening compliance after the
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introduction of tele-ophthalmology (V) and the proportion of screening examinations
with tele-ophthalmology based on screening preference (T), as follows
P(tele)= T ( P(ref) х V ) , V ≥ 1, P(tele) <1

(1)

In this equation, “P(ref) х V” is the overall screening rate for Arm 2, and “P(tele)” is the
proportion of those examinations from Arm 2 that correspond to tele-ophthalmology
screening.
Both patients’ preferences (T) and screening compliance after tele-ophthalmology (V)
were derived from published literature. For this purpose, a structured literature search
was performed among Medline and EMBASE databases using the subject headings
“telemedicine”, “mobile health units”, “mass screening”, “early diagnosis”, “community
pharmacy service” (appendix H). Priority was given to studies from primary care
screening services using mobile screening units in urban or semi-urban settings. For the
base-case model, the volume increase in DR examinations after tele-screening (V) was
set to 10%, with 40% of patients favoring pharmacy-based telescreening examination
over the comparator.18,37,38 Hence, the base-case screening probability for the teleophthalmology arm (Figure 4.1, Arm 2) was 0.562. For detailed calculations of model
probabilities, refer to appendix I.
Estimates of the diagnostic performance of tele-ophthalmology were obtained from a
recent meta-analysis39 that separately reported the summary results according to
diagnostic threshold. Therefore, we used the summary sensitivity and specificity
corresponding to the assessment of any DR, and derived the diagnostic performance of
in-person examination from one of the included studies.40 We also used this data to
calculate the proportion of unreadable images with tele-ophthalmology with and
without pharmacologic dilation. Finally, the proportion of dilated examinations was
obtained from a study that used pharmacy-based tele-ophthalmology for DR screening
across Canadian provinces.41 It was assumed that pupil dilation with tropicamide or
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phenylephrine was performed by the pharmacist at the patient’s discretion. All
probabilities used in the economic model are outlined in appendix J
4.2.4 Identification and calculation of model costs
Data sources for estimates of costs included published literature, market prices,
vendor’s quotations, official government reports and administrative information from
St. Joseph’s Healthcare in London (ON). Only direct costs were incorporated into the
model and presented in 2013 Canadian dollars.
Cost information is provided in Table 4.2. Equipment for the tele-ophthalmology
program consisted of a non-mydriatic digital fundus camera, a carrying case, an
adjustable table, a laptop and reading software. Costs related to equipment and
maintenance were obtained directly from the vendor and was given a 5 year life
(written communication, 2013). Capital costs were annualized at a 5% discount rate per
year, corresponding to the rate for Ontario government bonds.42 In contrast, capital
costs for in-person examination were not included, as the ophthalmoscope and lens are
already bought and routinely used for any eye examination.
Traveling costs of the mobile retinal unit consisted on van rental cost (including
insurance) and fuel expenses for traveling across the Chatham-Kent municipality. Rental
costs estimates were provided from the vendor; fuel costs were obtained from the
Ontario Ministry of Energy report and reflected the cost per gallon in Ontario.43
Pharmacy overhead costs were calculated from the annual Pharmacy Trends Reports,
which provided information on annual operating expenses per square foot among
Canadian pharmacies.44 Thus, we adjusted the cost to the part-time use of pharmacy
space in 2013 Canadian dollars.
Technician costs for tele-ophthalmology were based on current prevailing wages
provided by administrators at St. Joseph’s Hospital in London (written communication,
2013). To estimate the labor cost per patient assessment, a structured literature search
was conducted with Medline and EMBASE to find economic studies on DR screening
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that reported information on average minutes of labor cost per patient. Subject
headings included “diabetic retinopathy”, “diagnostic imaging”, “cost allocation”,
“healthcare costs” (appendix K). Six studies calculated the average minutes spent by
personnel for taking and/or assessing eye photographs, which varied between 5 and 15
minutes.24,45–49 Based on this information, we extrapolated the cost per hour of
technician labour to the cost per patient assessment with the tele-ophthalmology
program.
In-person consultation fees for major eye examination were obtained from the Schedule
of Benefits of Physician Services by the Ontario Ministry of Health and Long-term care.50
The ophthalmic reader fee was based on the tele-consultation fee provided by the
Alberta Healthcare Insurance Plan for pediatricians and related subspecialties.51 It was
assumed that an Ontario tele-consultation fee for DR assessment would resemble that
of Alberta for tele-consultation in pediatric specialties. Patient referral costs and
consumables costs were obtained from vendors’ quotations and administrative
information from St. Joseph’s Health Care (London, ON).
4.2.5 Cost-effectiveness evaluation and sensitivity analysis
Two measures of effectiveness were analyzed in this study; (1) cases of any DR detected
(true positives) and (2) cases correctly diagnosed (including true positives and true
negatives). A case of DR was defined as any DR beyond very mild non-proliferative DR,
corresponding to a Modified Airlie House Classification ≥20 on the reference standard.33
Cost- effectiveness was calculated as total cost divided by number of cases detected (or
number of cases correctly diagnosed). Thus, the Incremental Cost Effectiveness Ratio
(ICER) was calculated as the extra cost needed to generate (1) an additional case of DR
or (2) an additional case correctly diagnosed after the implementation of pharmacybased tele-ophthalmology.52
Deterministic Sensitivity Analysis
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Parameters considered as potential drivers of the model were included in sensitivity
analysis, and were assigned plausible ranges based on 95% confidence intervals or
upper and lower 25% limits around the base-case value. For simplicity we limited the
reporting of sensitivity analyses to the cost per case detected per year.
One way sensitivity analyses were conducted for most data elements to investigate the
extent to which each variable’s uncertainty affected the model results. Variables
considered for one-way sensitivity analysis with their respective ranges are listed in
Table 4.1 (model probabilities) and Table 4.3 (model costs). A multi-way sensitivity
analysis was also performed, where model parameters were varied simultaneously to
generate extreme scenarios.
4.3 Results
4.3.1 Base-case analysis
In the base-case analysis we considered a tele-ophthalmology program that achieved a
10% volume increase in patient compliance, with a 0.18 probability of unreadable
images and pharmacologic dilation in 33% of examinations. Considering a population of
10,354 diabetic patients, the tele-ophthalmology program would correctly detect
additional 136 cases compared to in-person examination only (Table 4.4). Costeffectiveness was assessed as (1) cost per case detected, and (2) cost per case correctly
diagnosed. For (1) the cost-effectiveness of in-person examination and teleophthalmology was $510 and $478.3, respectively, whereas for (2) was $107 for inperson examination and $73.2 for tele-ophthalmology. The incremental costeffectiveness (ICER) was $314.1 per additional case detected and $102 per additional
case correctly diagnosed (Table 4.5). In both instances the programs were nondominant; hence, tele-ophthalmology was always more costly, but more effective than
in-person examination. (Figure 4.2).
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4.3.2 Sensitivity analyses
Sensitivity analyses assessed uncertainties of model parameters, including diagnostic
accuracy, DR prevalence, compliance and costs. Results of multiple one-way sensitivity
analyses are outlined in Table 4.6. We found that the model was stable with regards to
sensitivity, specificity and prevalence variations. Similar to a previous study,53 workforce
wages played a significant role in the cost-effectiveness of both screening programs. In
the case of tele-ophthalmology, we observed that the ICER doubled its base-case value
when the image reader’s fee (retina specialist) increased from $31.6 to $55.4 per
patient. This parameter is an important source of uncertainty since Ontario currently
does not have a tele-ophthalmology code that could serve as a reference for the model.
For the base-case scenario we used a proxy code from the Alberta Schedule of Medical
Benefits (code 03.05JJ).54 This code is used by pediatricians (including subspecialties) if
they provided a five minute evaluation or consultation by telephone or other
telecommunication methods, which is similar to the service a retina specialist would
provide in a category 1 tele-ophthalmology program.
Conversely, if the in-person examination fee increased from $51.1 to $78 per person,
tele-ophthalmology program dominated at a cost of $603 per true positive case
detected compared to $737 per case detected with in-person examination.
Other influential variables in the tele-ophthalmology program included the proportion
of unreadable images (without pupil dilation) and the grader fee. When the proportion
of unreadable images increased to 0.43, the ICER also increased to $411.2 per additional
case detected per year. Similarly, when the tele-ophthalmology grader fee per patient
incremented up to 25%, the ICER also increased to $633.9 per additional case detected
per year.
A two-way sensitivity analysis was conducted to estimate the joint influence of
screening volume and patients’ preferences on the cost-effectiveness of pharmacybased tele-ophthalmology. As expressed in equation (1), both parameters were used to
calculate the screening rate for both programs under the assumption that the two
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screening alternatives were available to the patients after the introduction of teleophthalmology (Arm 2). We defined a tele-ophthalmology preference range from 10%
to 100% and considered a volume increase of 10% (base-case) 15% and 20%. Teleophthalmology remained non-dominant in all combinations (Figure 4.3). Of note, the
lowest ICER was achieved when all screened patients used pharmacy-based teleophthalmology ($192 per additional case detected per year).
In the extreme scenario analyses, both costs and probabilities were manipulated to
generate alternative settings that would represent the best and the worst scenario for
the introduction of pharmacy-based tele-ophthalmology. In the best-case scenario,
influential parameters were defined as follows: patient preference for tele-screening
increased to 0.70 (assuming all patients had a dilated examination), tele-screening
diagnostic performance was defined according to upper 95% confidence intervals for
sensitivity and specificity (Se 91%, Sp 97%), while in-person examination was set to its
lowest diagnostic performance (Se 67% Sp 79%). Also, the rate of unreadable images for
tele-ophthalmology was fixed at its lowest value (3.3%). Finally, fees corresponding to
the tele-ophthalmology coordinator, ophthalmic photographer and the retina expert
grading were reduced by 15% ($20.5, $20.5 and $23.75 respectively). We found that
tele-ophthalmology dominated at $367.6 per case detected per year, being less costly
and more effective than in-person examination ($575.1 per case detected per year).
Alternatively, the worst case scenario was fixed under the poorest diagnostic
performance for tele-screening (Se 76%; Sp 90%) and the best sensitivity and specificity
values for in-person examination (Se 83%; Sp 86%), the highest rate of unreadable
images (43.5%) and a 15% increase in the coordinator, eye photographer and retina
expert fee ($34.21, $34.21 and $55.21, respectively). In this scenario, teleophthalmology remained undominated although the incremental cost-effectiveness was
four times higher than the base-case ($1,393 per additional case detected per year).
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4.4 Discussion
4.4.1 Cost-effectiveness of tele-ophthalmology
The detection of DR by means of tele-ophthalmology programs has proven to be a costeffective alternative amongst isolated communities, generating savings through lower
transportation and personnel costs.17,25 In terms of total annual costs, the introduction
of tele-ophthalmology was more expensive than in-person examination but detected
15% more cases of any DR at $314.1 per additional case. In the Chatham-Kent context,
this was translated to 528 more patients attending eye examination, and 136 additional
DR cases detected.
A previous study assessed the cost-effectiveness of systematic photographic screening
versus opportunistic eye examination in the UK.46 Adjusted to 2013 Canadian dollars,
the incremental cost per additional DR case detected was $83, which was regarded as
cost-effective within the British healthcare system. In comparison, the incremental costeffectiveness of tele-ophthalmology may be too high to consider its implementation in a
semi-urban context. However, if an exclusive use of tele-ophthalmology is assumed, the
ICER would be reduced to $192 per case detected, almost half of the base-case value
and closer to the acceptable cost-effectiveness estimate reported by James and
colleagues.46
4.4.2 Sensitivity analyses
Sensitivity analyses showed an important influence of healthcare specialists’ fees for inperson examination and interpretation of retinal images. As expected, the ICER
increased as the fee of retinal image readers increased up to 15% its base-case value.
Alternatively, when in-person examination cost reached $78 per patient, teleophthalmology became less costly and more effective, dominating over in-person
examination.
Undilated tele-screening examinations showed a higher rate of unreadable images,
which affected the incremental cost-effectiveness of the program. Although pupil
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dilation may improve image quality and lower the costs, it may prevent patients for
getting screened at the pharmacy, as reported in previous studies.41,55 Hence, the option
of including pharmacologic dilation will depend on the overall goal of the teleophthalmology program.16 For example, if the primary concern is to assess more
patients, then a program without pharmacologic dilation would be convenient, at the
expense of increasing the proportion of unreadable images.
4.4.3 Comparison to previous evidence
In contrast to our findings, other studies have reported tele-ophthalmology to be highly
cost-effective or even dominant at the base-case analysis.24,56,57 However, comparisons
of our results with prior published studies are not straightforward due to differences in
effectiveness outcomes and model assumptions. For instance, Whited and collaborators
used data from three US agencies to build nine economic models based on the Joslin
Vision tele-ophthalmology system.24 Tele-ophthalmology dominated clinic-based
ophthalmoscopy in seven models, and was cost-effective at extra $1,618 (2004 US
dollars) per additional case treated in the remaining two models. In contrast to our
model, this study assumed an exclusive initial use of the tele-ophthalmology alternative,
and its diabetic population was eight to twenty times bigger than in Chatham-Kent,
assuring maximum efficiency of both labor and equipment.
In the Canadian context, Maberley et al.,25 evaluated the introduction of a teleophthalmology system in a First Nations community, where retina specialists traveled
twice a year to make eye-examinations. Similarly, Aoki et al., assessed the introduction
of a tele-ophthalmology program in a remote US prison versus current practice
consisting on sporadic eye examinations by eye specialists.56 Both studies assessed the
cost-effectiveness of an alternative tele-ophthalmology program in terms of qualityadjusted life-years (QALY), and found tele-ophthalmology to be dominant over current
practice.25,56 The context in which these studies were framed differs greatly from the
semi-urban scenario used in our model, as they assumed an exclusive use of the teleophthalmology program. Costs of in-person examinations are superior in remote areas,

97

as usually includes transportation costs of either patients or healthcare personnel to
meet eye-screening needs. Hence, the capital cost of the tele-ophthalmology program is
by far justified in isolated communities through lower personnel and transportation
costs.
4.4.4 Strengths and limitations
To our knowledge, this is the first study that models the introduction of a tele-screening
program in a semi-urban population without considering exclusive initial use of this
technology. Although the exclusivity assumption is commonly used in cost-effectiveness
analyses, it is very unlikely that a new tele-ophthalmology program would entirely
replace in-person examination in a context where primary care professionals are
permanently available.18,19 We also contemplated key variables of tele-ophthalmology
systems such as need for pharmacologic dilation and rate of unreadable images, and
evaluated their influence on the cost-effectiveness of a category 1 tele-ophthalmology
program.16
Our model has some limitations worth noting. First, the present study was tailored to
the Chatham-Kent community. Patient pool size and prevalence was captured from
provincial reports; costs were derived from provincial information and administrative
data from St. Joseph’s healthcare in London (ON). Although aligned with the study
objectives, such specificity limits the applicability of these results to other settings.
However, the model structure of this analysis can be used in upcoming studies for the
evaluation of DR screening programs in similar geographic contexts. Second, the study
was conducted from a healthcare payer perspective, and indirect costs were not
included. Nonetheless, a societal perspective would likely favor the implementation of
tele-ophthalmology due to the inclusion of travel costs avoided and reduced time away
from work.59 Third, we used number of true positive cases detected (and number of
cases correctly diagnosed) as our effectiveness outcome. Although this is a clinically
intuitive measure that provides useful insight regarding the comparative costeffectiveness of interventions, it does not reflect the full effectiveness of the program as
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it does not take into consideration the therapeutic endpoint (e.g cases of blindness
averted, prevention of SVL). It also limited the direct comparison of our results with
other studies that used preference-based measures (e.g QALYs).
4.4.5 Study applicability
This study opens the discussion as if the benefits of mobile tele-ophthalmology in semiurban areas are equivalent to those benefits observed in remote populations. In a semiurban community, the implementation of tele-ophthalmology would be almost three
times more expensive compared to a context where the tele-ophthalmology program is
assumed to be exclusive. Although our results suggest increased benefits of teleophthalmology versus in-person examination in terms of more patients being screened
and additional DR cases being detected, the incremental cost of $314 per case may be
considered too high to be implemented in a publicly funded healthcare system. This is
largely due to the fact that the healthcare payer would still have to support in-person
examination in addition to the new telescreening program, especially during early
stages of program execution.
If stakeholders are interested in investing on a telescreening program in a semi-urban
context, a comprehensive discussion about potential strategies to reduce screening
costs should be in order.60 From the sensitivity analyses, we found that eye specialist
fees and pupil dilation are the most influential factors in the cost-effectiveness of the
tele-ophthalmology program. Given that pharmacologic dilation reduces the proportion
of unnecessary referrals due to unreadable images, a program with pupil dilation to all
patients will improve cost-effectiveness. Also, the automated detection of DR lesions is
an alternative to the manual assessment of digital images by a specialist.61
It is worth noting that our interpretation is based on the incremental cost per case
detected. Clinical outcomes such as cases of SVL averted or cases of blindness prevented
were out of the scope of this study. Economic studies based on rural communities have
found an increased benefit of tele-ophthalmology in terms of clinical outcomes and
quality of life.25,47,62,63 It is possible that tele-ophthalmology may offer great benefits in
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terms of cases of SVL averted or QALYs in a semi-urban context, which would justify the
initial investment in equipment and labor. Further studies should expand on the analysis
based on these important clinical endpoints to gain a better understanding about the
overall benefits of tele-ophthalmology in the semi-urban context.
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4.6 Tables and figures

Figure 4.1 Illustration of a portion of decision tree showing competing alternatives for diabetic
retinopathy screening. Arm 1 corresponds to current practice (in-person examination); Arm 2
corresponds to the new intervention evaluated in the model (pharmacy-based teleophthalmology)

Table 4.1. Base case model parameters and parameter ranges
Parameter

Value

Range
(interval
for DTA)

Source

Fixed Data Elements
Diabetic population in study
setting

10,354
patients

-

Booth GL et al, 2012

Eye examination rate with
current practice

0.511

-

Buhrmann, Assaad, Hux, Tang, &
Sykora, 2003

Volume increase of screening
compliance after teleophthalmology is
implemented

10%
increase

-

Olayiwola et al., 2011; Vargas-Sánchez,
Maldonado-Valenzuela, Pérez-Durillo,
González-Calvo, & Pérez-Milena, n.d

Variable Data Elements
Prevalence of any DR in
Canada

0.225

0.169 to
0.281

a) Screening intervention parameters (tele-ophthalmology)

National Coalition for Vision Health,
2007; Public Health Agency of Canada,
2011
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Proportion prefers teleophthalmology for DR
screening

0.40

0.50; 0.60;
0.70

Leese, Newton, Jung, Haining, &
Ellingford, 1992; Taylor et al., 2007;
García Serrano et al., n.d.

Proportion examined with
tele-ophthalmology*

0.225

0.169 to
0.281

Leese, Newton, Jung, Haining, &
Ellingford, 1992; Taylor et al., 2007

Sensitivity

0.84

Coronado et al., 2013

Specificity

0.94

Proportion of dilated
examinations

0.337

(95% CI)
0.76 - 0.91
(95% CI)
0.90 - 0.97
(95% CI)
0.25-0.47

Proportion of unreadable
images with pupil dilation

0.054

(95% CI)
0.0330.076

Coronado et al., 2013

Proportion of unreadable
images without pupil dilation

0.287

(95% CI)
0.1390.435

Coronado et al., 2013

b) Current practice parameters (in-person examination)
Proportion examined with current 0.337
0.253 to
practice (Pc) after introduction of
0.421
tele-ophthalmology*
Sensitivity
0.75
(95% CI)
0.67-0.83
Specificity
0.82
(95% CI)
0.79-0.86

Coronado et al., 2013
Boucher et al., 2008

Leese, Newton, Jung, Haining, &
Ellingford, 1992; Taylor et al., 2007
Olson et al., 2003
Olson et al., 2003

DTA=Deterministic sensitivity analysis; DR=Diabetic Retinopathy
* Based on published data estimates about proportion of patients screened after introduction of tele-ophthalmology and
patient preferences towards examination with tele-ophthalmology. For detailed calculations refer to Appendix I

Table 4.2 Estimated costs for in-person examination and pharmacy-based teleophthalmology
Item

Cost per unit

Unit
description

Total cost

Capital costs*

Data source

Cost/year

Digital Camera

$

17,458.50

Table Lift

$

1,045.25

Software

$

1,610.25

Carrying case

$

1,299.50

Maintenance

$

460.00

One retinal
camera
One table lift
One software
package
One carrying
case
Annual

$

4,032.45

Vendor's quotation

$

241.43

Vendor's quotation

$

371.93

Vendor's quotation

$

300.15

Vendor's quotation

$

460.00

Vendor's quotation
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maintenance
Camera transportation costs

Cost/year

Van rent

$

91.07

One cargo
van

$

1,092.84

Fuel

$

1.27

One litre

$

76.26

Overhead costs†
Pharmacy
overhead costs
Labour costs
Teleophthalmology
coordinator

Vendor's quotation
Ontario Ministry of
Energy, Ontario prices
2013

Cost/year
$

155.00

Annual
expenditures
per square
foot

$

775.00

10th annual Pharmacy
Trends Report, 2004

Cost/patient
$

24.18

Hourly wage£

$

4.03ɸ

St. Joseph's Hospital
administrative data

Photographer

$

24.18

Hourly wage£

$

6.05ɸ

Grader
(ophthalmologist)

$

31.66

Consultation
per patient

$

31.66

Eye care
specialist

$

51.10

Consultation
per patient

$

51.10

St. Joseph's Hospital
administrative data
Alberta Healthcare
Insurance plan
Ontario Ministry of
Health and Long-term
Care

Consumables
Referral to retina
specialist
Dilation dropsTropicamide 1%
Dilation dropsphenylephrine
2.5%
Chin covers

Cost/patient
$

111.31

$

16.15

$

4.82

$

56.50

Examination
per patient
Cost per unit
(15 ml)

St. Joseph's Hospital
administrative data
St. Joseph's Hospital,
pharmacy data

$

111.31

$

0.54

Cost per unit
(5 ml)

$

0.120

St. Joseph's Hospital,
pharmacy data

Cost per pack
(500)

$

0.113

Vendor's quotation

*Annualized based on a 5-year life equipment and a 5% depreciation rate
†Based on average annual pharmacy overhead expenditures for 5 square feet, adjusted to inﬂa on
£
Based on a part-time annual salary of $21,762.
ɸ
Part-time salary was extrapolatedaccording to the number of patients per hour. Workload estimation was defined
based on literature searches (see appendix K)

Table 4.3 Cost ranges used for Deterministic Sensitivity Analysis
Item
Capital costs
Digital Camera
Labour costs
Tele-ophthalmology
coordinator
Photographer

Unit description

One retinal camera
Consultation per
patient
Consultation per
patient

Value or Range†
(for DSA)

Cost

$

17,458.50

$

29,798.10

Hourly wage

$24.18

Hourly wage

$24.18
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Grader
(ophthalmologist)

Consultation per
$
patient
Consultation per
Eye care specialist
$
patient
† Range based on upper and lower 25% limits

31.66
51.10

$ 23.75 to $ 55.41
$ 38.33 to $ 89.43

Table 4.4 Examination outcomes of pharmacy-based tele-ophthalmology and in-person
examination programs per 10,354 diabetic patients in the study model

Patient compliance (%)
True positive
True negative
False positive
False negative
Total patients screened

In-person
examination

Introduction of teleophthalmology

51.1%
893
3362
738
298
5291

56.2%
1029
3914
595
280
5819

Table 4.5 Incremental cost-effectiveness results for in-person examination versus
introduction of tele-ophthalmology
Screening
stategy
In-person
screening
(primary care)
Introduction of
Teleophthalmology

Cost per
patient

Incremental
cost per
patient

$43.98

$49.22

Effectiveness
(case
detected)

Incremental
effectiveness

ICER

0.086

$5.24

0.103

Dominance

Undominated

0.017

$314.1

Undominated
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Figure 4.2 Cost-effectiveness plane. In-person examination versus introduction of teleophthalmology

Deterministic Sensitivity Analysis

ICER ($/case detected per year)

Δ V= Volume increase of screened patients after introduction of teleophthalmology
500.00
450.00
400.00

Δ
V=10%
Δ
V=15%

350.00
300.00
250.00
200.00
150.00
100.00
0.1

0.2

0.3 0.4 0.5 0.6 0.7 0.8
Tele-ophthalmology preference

0.9

1

Figure 4.3 Two way sensitivity analysis. Influence of tele-ophthalmology preference and
increased patience compliance after introduction of tele-ophthalmology on the
incremental cost-effectiveness ratio (ICER)
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Table 4.6 One-way deterministic sensitivity analysis results
Base-case
value

Range

ICER
($/case detected per
year)

Prevalence of any diabetic retinopathy

0.225

0.169 to 0.281

$ 394.4 to $ 265.89

Patient preference for pharmacy-based
tele-ophthalmology

0.40

0.40 to 0.70

$ 314.15 to $ 236.56

0.75
0.82

0.67 to 0.83
0.79 to 0.86

$ 282.0 to $ 361.2
$ 287.0 to $ 350.2

0.84
0.94

0.76 to 0.91
0.90 to 0.97

$ 405.9 to $ 304.9
$ 350.9 to $ 286.6

0.337

0.25 to 0.47

$ 333.9 to $ 321.5

Parameter

Diagnostic accuracy in-person
examination
Sensitivity
Specificity
Diagnostic accuracy tele-ophthalmology
Sensitivity
Specificity
Proportion of dilated examinations
(tele-ophthalmology)

Rate of unreadable images (tele-ophthalmology)
With pupil dilation

0.054

0.033 to 0.076

$ 306.6 to $ 321.5

Without pupil dilation

0.287

0.139 to 0.435

$ 209.9 to $ 411.2

$31.66

$ 23.75 to $
55.41

$ 207.6 to $ 633.9

$3.02 to $5.04

$300 to $327.8

$6.05

$4.54 to $7.56

$300.05 to $327.8

$51.10

$ 38.33 to $
89.43

Tele-ophthalmology
dominates at $ 77

$ 83.48 to $
139.14

$ 252.5 to $ 375.8

Grader fee per patient (teleophthalmology)
Tele-ophthalmology coordinator fee per
patient
Ophthalmic photographer
In-person consultation
Referral to retina specialist

$4.03

$111.31
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Chapter 5 Integrated discussion
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5.1 Overview
This chapter outlines the thesis results and implications, and when appropriate it
expands on the methodology used and interpretation of results. In summary, the
purpose of this thesis was twofold: To assess the diagnostic accuracy of teleophthalmology for DR screening, and incorporate these findings in an economic model
to explore the cost-effectiveness of a pharmacy-based tele-ophthalmology program in a
semi-urban area.
5.2 Integrated discussion of thesis results
Chapter 3 of this thesis examined the diagnostic accuracy of tele-ophthalmology
strategies for DR screening in adults as compared to reference standards. We conducted
a systematic review in multiple databases from 1998 to 2012 (last update March 2013),
and performed a meta-analysis categorizing results according to diagnostic threshold
reported.
Results suggested that tele-ophthalmology programs fulfilled the minimum
effectiveness requirements advised by the Canadian Ophthalmological Society
(sensitivity over 80%, specificity between 90% and 95%).1 For the detection of referable
DR, we observed that the use of a single field per eye had a negative influence in the
diagnostic performance of tele-ophthalmology programs, whereas the use of multiple
photographic fields improved both sensitivity and specificity. For the detection of early
DR forms, we found that the choice of reference standard affected the study results, in
that studies that used 7-field fundus photographs (as advised by the American
Telemedicine Association2) showed better sensitivity compared to studies that selected
ophthalmologic examination as the reference. This is supported by previous evidence
that shows that inaccurate reference standards underestimate the diagnostic accuracy
of a test, being sensitivity more affected than specificity estimates.3,4 We also observed
that diagnostic performance for the detection of any DR improved over time. This is
likely attributed to advances of digital camera technologies and data transmission
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techniques, as a better resolution facilitates the identification of earlier signs of DR,
reducing the number of false negatives.5
In Chapter 04, we explored the cost-effectiveness of pharmacy-based teleophthalmology for diabetic retinopathy screening in semi-urban Southwestern Ontario.
Given that summary accuracy estimates were calculated for the detection of both any
DR and referable retinopathy, we decided to address the cost-effectiveness of a
category 1 tele-ophthalmology program, corresponding to the detection of any DR.2
These estimates were more suitable for the economic model than the results of
referable DR, since the definition of “any DR” was consistent amongst studies (ETDRS
≥20). Also, the summary prevalence was less variable across these studies compared to
studies that used referable retinopathy as screening threshold, and resembled that of
the Chatham-Kent population. Similarly, we used the meta-analysis information to
calculate the weighted average of unreadable images according to use of pharmacologic
dilation and incorporated these values into the economic model.
We found that pharmacy-based tele-ophthalmology was more costly, but more effective
than in-person examination, at $478.3 per case detected and an incremental costeffectiveness of $314.15 per additional case detected. Sensitivity analyses showed that
unreadable images and physician’s fees (for both in-person examination and teleophthalmology) influenced cost-effectiveness outcomes. In our model we discarded the
assumption of exclusive initial use of tele-ophthalmology, as this situation would be
highly unlikely in a semi-urban area where eye care specialists are permanently
available. However, if we consider this assumption, the incremental cost-effectiveness
decreases to $73.23 per additional case detected.
5.3 Thesis limitations and knowledge gaps in current literature
Meta-analyses of diagnostic test accuracy studies are particularly challenging as they
usually incorporate primary studies that differ in study design, levels of quality and
definition of test positivity.6 Hence, greater variability is expected amongst diagnostic
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accuracy studies versus clinical trial studies.7 As commented in chapter 03, we detected
substantial heterogeneity across studies, explored by means of subgroup analyses.
Amongst studies that detected any DR (category 1), heterogeneity was partially
explained by the differential use of reference standard and pharmacologic dilation.
Variability of the summary sensitivity was significantly reduced when low quality studies
were excluded from the analysis (Base-case I2=90; Q=154 vs. I2=31; Q=8.8) , reflecting
the influence of study design deficiencies on accuracy estimates. Hence, methodological
differences in study design, data collection and reporting of diagnostic accuracy
estimates may account for part of heterogeneity observed in the meta-analysis results
(methodological bias).8,9
In contrast to our findings amongst category 1 studies (detection of any DR),
considerable heterogeneity remained unexplained even after subgroup and sensitivity
analyses on studies that detected referable DR (category 2). In this case, heterogeneity
could be partially explained by a threshold effect, since authors in this category used
diverse guidelines (or even personal criteria) to define test positivity. There may be
other significant sources of heterogeneity that we could not address in our analysis due
to the small number of primary studies within subgroups, or lack of adequate reporting
in primary studies (discussed below).
Variability due to clinical characteristics was not addressed in this thesis, as this
information was poorly reported in primary studies. For instance, only 50% of studies
presented information about ethnicity, type of diabetes and duration of diabetes. Lack
of clinical and demographic information limits the interpretation of the actual
usefulness of tele-ophthalmology screening program. This also impacts the
interpretability of the economic analysis findings; it could be possible that some patient
subgroups may have greater benefit from a pharmacy-based tele-screening program. In
addition to the lack of reporting of clinical characteristics, index technology details such
as camera resolution, image compression, screen display size and resolution were not
described in most studies, restricting the assessment of the potential effect of these
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technological features on the diagnostic performance of screening programs in the
public health setting. However, we were able to evaluate the influence of number of
photographic fields per eye and pharmacologic dilation on the diagnostic performance
of tele-ophthalmology programs, which have been subject of intense debate amongst
experts regarding their relevance on the diagnostic yield of this procedure.10,11
Although methodological quality of primary studies was satisfactory, we detected a high
risk of patient selection bias and risk of bias due to exclusion of patients with
uninterpretable test results. Most of excluded patients presented comorbidities (e.g
cataracts) that restricted image interpretation. An inadequate selection of patients, as in
this case, may lead to an overestimation of sensitivity and specificity.12 Even though this
is considered a source of bias by some authors, evidence regarding the effect of
exclusion of patients due to uninterpretable results is very limited, and a definitive
association with inflated diagnostic accuracy estimates has not been demonstrated.13
In the economic analysis, we chose the detection of any DR as the threshold for test
positivity, which by definition corresponds to a Category 1 telehealth program.2 The
main objective of this program is to increase adherence to screening standards amongst
diabetic patients, and serve as a platform for surveillance and education of those
individuals at risk of developing DR. However, direct management and treatment of
potential cases of severe vision loss correspond to more complex telemedicine
programs that use additional features such as stereopsis that permit an accurate
categorization of DR severity levels, including detection of diabetic macular edema.14
Hence, the interpretation of the cost-effectiveness estimates is limited to the
incremental cost per additional case detected and the incremental cost per case
correctly diagnosed.
Although macular edema is a very important complication from DR, tele-ophthalmology
programs without stereopsis (e.g Category 1 and 2 telehealth programs) are technically
limited to assess this condition.2 However, several studies have found that early clinical
signs of DR detected in tele-ophthalmology examinations may act as proxy indicators for
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clinically significant macular edema.15,16 From the meta-analysis, we examined primary
studies that reported diagnosis of macular edema, and found that 32 out of 33 cases
were detected along with DR cases.17–19 Hence, a combination of digital photography
and visual acuity estimation may be useful to evaluate the presence of clinically
significant macular edema in a category 1 telehealth program. Validation studies must
be conducted to explore this alternative.
5.4 Conclusions and future directions
Our study indicated that diagnostic performance of tele-ophthalmology programs is
satisfactory and fulfills Canadian Ophthalmological Society’s criteria for DR screening
(sensitivity >80%, specificity between 90% and 95%)1. However, the clinical significance
of these findings is somewhat inconclusive due to the presence of significant
heterogeneity, which remained partially unexplained after subgroup and sensitivity
analyses. Hence, careful judgment should be exercised when interpreting the
applicability of these summary estimates in clinical practice.
Of note, we found lack of reporting of important clinical characteristics and technology
features, which in turn limited the assessment of these variables in the meta-analysis.
This is an issue of paramount importance that should be addressed by investigators and
journal editors, as an adequate reporting of these features will warrant a
comprehensive examination of sources of variation in future reviews.20
Although the diagnostic performance of tele-ophthalmology was satisfactory, the costeffectiveness of a pharmacy-based tele-ophthalmology program in a semi-urban
population is unclear. While this program was more effective than in-person
examination, an additional cost of $314.1 per case detected may be too high from the
healthcare payer perspective. Hence, this economic analysis opens the discussion as if
the benefits of mobile tele-ophthalmology in semi-urban areas are equivalent to those
benefits observed in remote populations. Prospective studies will provide more insight
on the impact of such programs on prevention of severe vision loss and quality of life in
a semi-urban setting.
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Appendix A. Meta-analysis of Observational Studies in Epidemiology (MOOSE) checklist

Reporting background should include
Problem definition
Hypothesis statement
Description
Type of exposure or intervention used
Type of study designs used
Study population
Reporting of search strategy should include
Qualifications of searches (e.g. librarians and investigators)
Search strategy, including time period included in the synthesis and
keywords
Effort to include all available studies, including contact with authors
Databases and registries searched
Search software used, name and version, including special features
Use of hand searching (e.g. reference lists of obtained articles)
List of citations located and those excluded including justification
Method of addressing articles published in languages other than English
Method of handling abstracts and unpublished studies
Description of any contact with authors
Reporting methods should include
Description of relevance or appropriateness of studies assembled for
assessing the hypothesis to be tested
Rationale for the selection and coding of data (eg, sound clinical principles
or convenience)
Documentation of how data were classified and coded (eg, multiple raters,
blinding, and interrater reliability)
Assessment of confounding (eg, comparability of cases and controls in
studies where appropriate)
Assessment of study quality, including blinding of quality assessors;
stratification or regression on possible predictors of study results
Assessment of heterogeneity
Description of statistical methods (eg, complete description of fixed or
random effects models, justification of whether the chosen models account
for predictors of study results, dose-response models, or cumulative metaanalysis) in sufficient detail to be replicated
Provision of appropriate tables and graphics
Reporting of results should include
Graphic summarizing individual study estimates and overall estimate
Table giving descriptive information for each study included
Results of sensitivity testing (eg, subgroup analysis)
Indication of statistical uncertainty of findings
Reporting of discussion should include

Page
48
48
48
48, 49
49
49
49, 50
48,
Appendix

49,50
48
49
49
72
50
54
50
50
49,50
51
52,53
51, 52
72-81
78, 79
73
81
61

C
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Quantitative assessment of bias (eg, publication bias)
Justification for exclusion (eg, exclusion of non–English-language citations)
Assessment of quality of included studies
Reporting of conclusions should include
Consideration of alternative explanations for observed results
Generalization of the conclusions (ie, appropriate for the data presented
and within the domain of the literature review)
Guidelines for future research
Disclosure of funding source

53
54
55
60, 61
61
61
54
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Appendix B. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist

Checklist item

Reported
on page #

Section/topic

#

TITLE
Title

1

Identify the report as a systematic review, meta-analysis, or both.

2

Provide a structured summary including, as applicable: background; objectives; data sources; study
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results;
limitations; conclusions and implications of key findings; systematic review registration number.

Rationale

3

Describe the rationale for the review in the context of what is already known.

48

Objectives

4

Provide an explicit statement of questions being addressed with reference to participants, interventions,
comparisons, outcomes, and study design (PICOS).

48

Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available,
provide registration information including registration number.
Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years
considered, language, publication status) used as criteria for eligibility, giving rationale.
Describe all information sources (e.g., databases with dates of coverage, contact with study authors to
identify additional studies) in the search and date last searched.
Present full electronic search strategy for at least one database, including any limits used, such that it
could be repeated.
State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if
applicable, included in the meta-analysis).
Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and
any processes for obtaining and confirming data from investigators.

-

46

ABSTRACT
Structured
summary

-

INTRODUCTION

METHODS
Protocol and
registration

5

Eligibility criteria

6

Information
sources

7

Search

8

Study selection

9

Data collection
process

10

49
48, 49
App. C
49
49, 50
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Data items
Risk of bias in
individual
studies
Summary
measures
Synthesis of
results
Risk of bias
across studies
Additional
analyses

11
12
13
14
15
16

List and define all variables for which data were sought (e.g., PICOS, funding sources) and any
assumptions and simplifications made.
Describe methods used for assessing risk of bias of individual studies (including specification of whether
this was done at the study or outcome level), and how this information is to be used in any data
synthesis.

50

State the principal summary measures (e.g., risk ratio, difference in means).

52

Describe the methods of handling data and combining results of studies, if done, including measures of
consistency (e.g., I2) for each meta-analysis.
Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias,
selective reporting within studies).
Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done,
indicating which were pre-specified.

53

52, 53
53, 54
53

RESULTS
Study selection
Study
characteristics
Risk of bias
within studies
Results of
individual
studies
Synthesis of
results
Risk of bias
across studies
Additional

17
18
19
20
21
22
23

Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for
exclusions at each stage, ideally with a flow diagram.
For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up
period) and provide the citations.
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Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).

77, 78, 83

For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
Present results of each meta-analysis done, including confidence intervals and measures of consistency.

73

78, 79

79

Present results of any assessment of risk of bias across studies (see Item 15).

77, 78

Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see

81, 82
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analysis
DISCUSSION
Summary of
evidence

Item 16]).

24

Limitations

25

Conclusions

26

Summarize the main findings including the strength of evidence for each main outcome; consider their
relevance to key groups (e.g., healthcare providers, users, and policy makers).
Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete
retrieval of identified research, reporting bias).
Provide a general interpretation of the results in the context of other evidence, and implications for
future research.

59

Describe sources of funding for the systematic review and other support (e.g., supply of data); role of
funders for the systematic review.

54

60
61

FUNDING
Funding

27
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Appendix C Complete search strategies for primary databases
C.1. Medline search strategy (OVID)
#
1
2

3

4
5
6

7
8
9

10
11
12
13
14
15
16
17

Search terms
Diabetic Retinopathy/ or macular edema/ or fundus oculi/
(diabetic retinopath$ or diabetic maculopath$ or macular edema or macular
oedema or fovea edema or fovea oedema or fundus oculi).mp. [mp=title,
abstract, original title, name of substance word, subject heading word, protocol
supplementary concept, rare disease supplementary concept, unique identifier]
(fundus adj10 (eye or retina$)).mp. [mp=title, abstract, original title, name of
substance word, subject heading word, protocol supplementary concept, rare
disease supplementary concept, unique identifier]
1 or 2 or 3
exp Diagnosis/ or diagnostic imaging/
diagnos$.mp. [mp=title, abstract, original title, name of substance word,
subject heading word, protocol supplementary concept, rare disease
supplementary concept, unique identifier]
5 or 6
telemedicine/ or telepathology/ or photography/ or vision screening/
(telescreen$ or automated screen$ or digital imag$ or tele-screen$ or
teleophthalmology or tele-ophthalmology or digital screen$ or photograph$ or
vision screen$ or image anal$ or telemedicine or telepathology or teleconsult$
or tele-consult$ or telehealth).mp.
8 or 9
exp "Sensitivity and Specificity"/ or comparative effectiveness research/ or exp
evaluation studies as topic/
(sensitiv$ and specificit$).mp.
evaluation studies.pt.
evaluation stud$.mp.
11 or 12 or 13 or 14
1 and 7 and 10 and 15
Limit 16 to yr=”1998-Current”

C.2. EMBASE search strategy (OVID)
#
1
2

3
4
5
6
7

Search terms
Diabetic Retinopathy/ or retina macula edema/ or eye fundus/
(diabetic retinopath$ or diabetic maculopath$ or macular edema or macular
oedema or macula edema or macula oedema or fovea edema or fovea oedema
or fundus oculi).mp.
(fundus adj5 (eye or retina$)).mp.
1 or 2 or 3
exp Diagnosis/ or diagnostic imaging/
diagnos$.mp.
5 or 6
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8
9

10
11
12
13
14
15
16

telemedicine/ or teleconsultation/ or telehealth/ or telepathology/ or exp
medical photography/ or image analysis/ or vision test/
(telescreen$ or automated screen$ or digital imag$ or tele-screen$ or telehealth
or teleconsult$ or tele-consult$ or teleophthalmology or tele-ophthalmology or
digital screen$ or medical photograph$ or vision screen$ or image anal$ or
telemedicine or telepathology).mp.
8 or 9
"Sensitivity and Specificity"/ or Comparative Studies/ or Comparative
Effectiveness/ or Evaluation/
(sensitiv$ and specificit$).mp.
(Comparative stud$ or comparative effectiveness or evaluat$).mp.
11 or 12 or 13
4 and 7 and 10 and 14
limit 20 to yr="1998 -Current"
C.3. BIOSIS search strategy (Web of Knowledge)

#
#1
#2
#3
#4
#5
#6

#7
#8
#9

Search terms
“diabetic retinopath*” or ”diabetic maculopath*” or “macular edema” or
“macular oedema” or “fovea edema” or “fovea oedema” or “fundus oculi”
fundus same (eye or retina*)
#1 or #2
Concept Codes=(Pathology - Diagnostic) OR Topic=(diagnos*)
Concept Codes=(Methods - Photography OR Public health - Health services
"and" medical care)
telescreen* or “automated screen*” or “digital imag*” or tele-screen* or
teleophthalmology or tele-ophthalmology or “digital screen*” or photograph*
or “vision screen*” or “image anal*” or telemedicine or telehealth or
telepathology or teleconsult* or ”tele-consult*”
#5 or #6
“comparative stud*" or "evaluation research" or "evaluation stud*" or
"comparative effectiveness" or (sensitiv* SAME specific*)
#8 AND #7 AND #4 AND #3
Timespan=1998-2012. Databases=BIOSIS Previews.
Lemmatization=On

C.4. Web of Science search strategy (Web of knowledge)
#
#1
#2

Search terms
“diabetic retinopath*” or ”diabetic maculopath*” or “macular edema” or
“macular oedema” or “fovea edema” or “fovea oedema” or “fundus oculi”
fundus same (eye or retina*)
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#3
#4
#5

#6
#7

#1 or #2
diagnos*
telehealth or teleconsult* or “tele-consult*” or telescreen* or "automated
screen*" or "digital imag*" or “tele-screen*” or teleophthalmology or teleophthalmology or "digital screen*" or photograph* or "vision screen*" or
"image anal*" or telemedicine or telepathology
“comparative stud*" or "evaluation research" or "evaluation stud*" or
"comparative effectiveness" or (sensitiv* SAME specific*)
#6 AND #5 AND #4 AND #3

C.5. Cochrane library search strategy (Wiley online library)
#
#1
#2
#3
#4

#5
#6
#7
#8
#9
#10
#11
#12
#13
#14
#15

#16
#17
#18
#19
#20
#21

Search terms
MeSH descriptor Diabetic Retinopathy, this term only
MeSH descriptor Macular Edema, this term only
MeSH descriptor Fundus Oculi, this term only
“diabetic retinopathy” or “diabetic retinopathies” or “diabetic maculopathy”
or “diabetic maculopathies” or macular edema or macular oedema or fovea
edema or fovea oedema or fundus oculi NEED “ “ around all phrases, eg
“fovea edema”
Fundus NEAR/5 (eye OR retina*)
#1 or #2 or #3 or #4 or #5
MeSH descriptor Diagnosis explode all trees
MeSH descriptor Diagnostic Imaging, this term only
diagnos*
#7 or #8 or #9
MeSH descriptor Telemedicine, this term only
MeSH descriptor Telepathology, this term only
MeSH descriptor Photography, this term only
MeSH descriptor Vision screening, this term only
telemedicine or telehealth or teleconsult or teleconsultation or "tele-consult"
or "tele-consultation" or telescreen or telescreening or "automated screen" or
"automated screening" or "digital images" or "digital imaging" or "digital
image" or "tele-screen" or "tele-screening" or teleophthalmology or "teleophthalmology" or "digital screen" or "digital screening" or photography or
photographic or "vision screening" or "vision screen" or "image analysis" or
telepathology
#11 or #12 or #13 or #14 or #15
MeSH descriptor Sensitivity and Specificity explode all trees
MeSH descriptor Comparative Effectiveness Research, this term only
MeSH descriptor Evaluation Studies as Topic explode all trees
(evaluation studies):pt
(sensitiv* and specificit*) or "comparative effectiveness" OR "evaluation

134

#22
#23

study" or "evaluation studies" or evaluat*
#17 OR #18 OR #19 OR #20 OR #21
#6 and #10 and #16 and #22 from 1998 to 2012

C.6. CINAHL Search strategy (EBSCO host)

#
S1
S2

S3
S4
S5
S6
S7
S8

S9

S10
S11
S12
S13
S14
S15
S16

Search terms
MH "Diabetic Retinopathy"
diabetic retinopath* or diabetic maculopath* or macular edema or macular
oedema or fovea edema or fovea oedema or fundus oculi NEED “ “ around all
phrases, eg “macular edema”
fundus N10 (eye or retina*)
S1 or S2 or S3
MH "Diagnosis" OR MH "Diagnosis, Eye+" OR MH "Diagnostic Imaging"
Diagnos*
S5 or S6
MH "Telehealth" OR MH "Telemedicine" OR MH "Remote Consultation" OR
MH "Telepathology" OR MH "Photography" OR MH "Digital Imaging" OR MH
"Vision Screening"
telescreen* or automated screen* or digital imag* or tele-screen* or
teleophthalmology or tele-ophthalmology or digital screen* or photograph*
or vision screen* or image anal* or telehealth or telepathology or
telemedicine or teleconsult* or “tele-consult*” or “remote consult*” NEED “
“ around all phrases, eg “automated screen*”
S8 or S9
MH "Sensitivity and Specificity" OR MH "Comparative Studies" OR MH
"Evaluation Research" OR MH "Summative Evaluation Research"
sensitiv* and specificit*
evaluation stud* NEED “ “ around all phrases,
S11 or S12 or S13
S4 and S7 and S10 and S14
S4 and S7 and S10 and S14
Limiters - Published Date from: 19980101-20121231
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Appendix D. Data collection form
Diagnostic accuracy of tele-ophthalmology for diabetic retinopathy screening
1. Study features
a) Citation (author, year)
b) Country
c) Language
d) Study objective
e) Funding source
2. Sample characteristics
a) Patient recruitment
b) Inclusion/exclusion criteria
c) Number of patients approached
d) Number of patients fully screened
e) Demographics

Yes
Age
Race/ethnicity

No

Mean (SD) OR Median (range) OR
proportion

Not
reported

Caucasian

Type I diabetes
Type II diabetes
Visual acuity
Any diabetic
retinopathy prevalence
Referable diabetic
retinopathy prevalence
Patient diagnosis
Definition of referable diabetic retinopathy (if applicable)

African-American

Hispanic

Other
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Eye
Patient
Not reported

f) Unit of study

3. Screening details

a) Reference standard used
7-field ETDRS photographs
Slit-lamp biomicroscopy
Not reported

b) Grading guideline used
Modified Airlie House Classification
European Field Guide
International Clinical Diabetic Retinopathy Scale
Other (please specify)
Not reported

c) Index technology
i.

Fundus camera

Camera brand
Camera resolution

ii.

Image acquisition (be as specific as possible)
Technician:
Certified photographer
Nurse
Eye care professional
Other (please specify)
Not reported

Number of fields taken per eye:
One
Two
Three
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Four
Five
More than five
Not reported

Field positioning:
Stereopsis
Yes
No
Not reported

Pupil dilation
Yes/mixed
No
Not reported

Mydriatic agent (if applicable):
iii.

Image quality

Yes

No

Not
reported

Proportion OR
compression ratio

Unreadable images (%)
Image compression

4. Diagnostic accuracy
Sensitivity
(95% CI)
Any Diabetic Retinopathy
Referable Diabetic Retinopathy

5. Additional comments of the reviewer

Specificity
(95% CI)

TP

FN

FP

TN
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Appendix E. Adapted QUADAS2 criteria
Phase 1: State the review question
Author:
Index test(s):
Reference standard:
Unit of study:
Phase 2: Draw a flow diagram for the
primary study
Phase 3: Risk of bias judgments
DOMAIN 1: Patient selection
a. Describe methods of patient
selection:
b. Signaling questions
Grading: If at least one “No”, then Risk of
bias is HIGH. If at least one “Unclear”,
then Risk of bias is “UNCLEAR”.
1) Was a consecutive or random
sample of patients enrolled?
Yes
No
Unclear

2) Did the study avoid inappropriate
exclusions?
Yes
No
Unclear
Could the selection of patients have
introduced bias?
RISK:
HIGH
LOW
UNCLEAR

DOMAIN 2: Index test(s)
Please complete for each index test
a. Describe the index test and how it
was conducted and interpreted:

b. Signalling questions
Grading: If at least one “No”, then Risk of
bias is HIGH. If at least one “Unclear”,
then Risk of bias is “UNCLEAR”.
3) Were the index test results
interpreted without knowledge of
the results of the reference
standard?
Yes
No
Unclear
4) If a threshold was used, was it
pre-specified?
Yes
No
Unclear
Could the conduct or interpretation of
the index test have introduced bias?
RISK:
HIGH
LOW
UNCLEAR
DOMAIN 3: Reference standard
a. Describe the reference standard
and how it was conducted and
interpreted:
b. Signalling questions
Grading: If at least one “No”, then Risk of
bias is HIGH. If at least one “Unclear”,
then Risk of bias is “UNCLEAR”.
5) Is the reference standard likely to
correctly classify the target
condition?
Yes
No
Unclear
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6) Were the reference standard
results interpreted without
knowledge of the results of the
index test?
Yes
No
Unclear
Could the reference standard, its
conduct, or its interpretation have
introduced bias?
RISK:
HIGH
LOW
UNCLEAR

DOMAIN 4: Flow and timing
a. Describe any patients who did not
receive the index test(s) and/or
reference standard or who were
excluded from the 2x2 table (refer
to flow diagram)
b. Describe the time interval or any
interventions between index
test(s) and the reference standard
c. Signaling questions
Grading: If at least one “No”, then Risk of
bias is HIGH. If at least one “Unclear”,
then Risk of bias is “UNCLEAR”.
7) Was there an appropriate interval
link between index test(s) and
reference standard?
Yes
No
Unclear

8) Did all patients receive the same
reference standards?
Yes
No
Unclear
9) Were all patients included in the
analysis?

Yes
No
Unclear
Could the patient flow have introduced
bias?
RISK: HIGH/LOW/UNCLEAR
HIGH
LOW
UNCLEAR
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Appendix F. Paired forest plots – Sensitivity analyses of included studies per category (category 1, detection of any diabetic retinopathy;
category 2, detection of referable diabetic retinopathy)

StudyId

SENSITIVITY (95% CI)

StudyId

SPECIFICITY (95% CI)

Ting SW et al., 2011

0.93 [0.81 - 0.99]

Ting SW et al., 2011

0.98 [0.93 - 1.00]

Molina-Fernandez et al., 2005

0.86 [0.57 - 0.98]

Molina-Fernandez et al., 2005

0.97 [0.85 - 1.00]

Maberley D et al., 2002

0.85 [0.70 - 0.94]

Maberley D et al., 2002

0.80 [0.68 - 0.89]

Lopez-Bastida et al., 2007

0.92 [0.88 - 0.95]

Lopez-Bastida et al., 2007

0.96 [0.93 - 0.98]

Boucher MC et al., 2003

0.98 [0.89 - 1.00]

Boucher MC et al., 2003

0.81 [0.64 - 0.93]

Baeza DM et al., 2009

0.85 [0.75 - 0.92]

Baeza DM et al., 2009

0.94 [0.89 - 0.97]

Baeza DM et al., 2004

0.88 [0.79 - 0.95]

Baeza DM et al., 2004

0.95 [0.89 - 0.98]

COMBINED

0.90[0.87 - 0.93]

COMBINED

StudyId

SPECIFICITY (95% CI)

Ting SW et al., 2011

0.93 [0.81 - 0.99]

Ting SW et al., 2011

0.98 [0.93 - 1.00]

Schiffman RM et al., 2005

0.99 [0.92 - 1.00]

Schiffman RM et al., 2005

1.00 [0.85 - 1.00]

Molina-Fernandez et al., 2005

0.86 [0.57 - 0.98]

Molina-Fernandez et al., 2005

0.97 [0.85 - 1.00]

Lopez-Bastida et al., 2007

0.92 [0.88 - 0.95]

Lopez-Bastida et al., 2007

0.96 [0.93 - 0.98]

Li HK et al., 2010

0.98 [0.91 - 1.00]

Li HK et al., 2010

0.92 [0.64 - 1.00]

Chun MDW et al., 2007

0.59 [0.42 - 0.74]

Chun MDW et al., 2007

1.00 [0.96 - 1.00]

Baeza DM et al., 2009

0.85 [0.75 - 0.92]

Baeza DM et al., 2009

0.94 [0.89 - 0.97]

Aptel F et al., 2008

0.95 [0.75 - 1.00]

Aptel F et al., 2008

0.98 [0.91 - 1.00]

Ahmed J et al., 2006

0.84 [0.64 - 0.95]

Ahmed J et al., 2006

0.86 [0.79 - 0.92]

COMBINED

0.91[0.83 - 0.96]

COMBINED

0.97[0.93 - 0.98]

Q = 34.53, df = 6.00, p = 0.00

I2 = 31.77 [0.00 - 90.05]
1.0
SENSITIVITY

SENSITIVITY (95% CI)

0.94[0.89 - 0.97]

Q = 8.79, df = 6.00, p = 0.19

0.6

StudyId

Q = 64.43, df = 8.00, p = 0.00

I2 = 82.62 [70.69 - 94.56]
0.6

1.0
SPECIFICITY

Figure 1a Category 1 studies – sensitivity analysis excluding studies with
high/uncertain risk of bias as graded by QUADAS2 criteria

Q = 53.39, df = 8.00, p = 0.00

I2 = 87.58 [80.80 - 94.37]
0.4

1.0
SENSITIVITY

I2 = 85.02 [76.39 - 93.64]
0.6

1.0
SPECIFICITY

Figure 1b Category 1 studies – sensitivity analysis excluding studies
published prior 2005
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Appendix F. (Continued)

StudyId

SENSITIVITY (95% CI)

StudyId

SPECIFICITY (95% CI)

Ting SW et al., 2011

0.93 [0.81 - 0.99]

Ting SW et al., 2011

0.98 [0.93 - 1.00]

Molina-Fernandez et al., 2005

0.86 [0.57 - 0.98]

Molina-Fernandez et al., 2005

0.97 [0.85 - 1.00]

Maberley D et al., 2002

0.85 [0.70 - 0.94]

Maberley D et al., 2002

0.80 [0.68 - 0.89]

Lopez-Bastida et al., 2007

0.92 [0.88 - 0.95]

Lopez-Bastida et al., 2007

0.96 [0.93 - 0.98]

Boucher MC et al., 2003

0.98 [0.89 - 1.00]

Boucher MC et al., 2003

0.81 [0.64 - 0.93]

Baeza DM et al., 2009

0.85 [0.75 - 0.92]

Baeza DM et al., 2009

0.94 [0.89 - 0.97]

Baeza DM et al., 2004

0.88 [0.79 - 0.95]

Baeza DM et al., 2004

0.95 [0.89 - 0.98]

COMBINED

0.90[0.87 - 0.93]

COMBINED

0.94[0.89 - 0.97]

Q = 8.79, df = 6.00, p = 0.19

1.0
SENSITIVITY

SENSITIVITY (95% CI)

1.0
SPECIFICITY

SPECIFICITY (95% CI)

0.81 [0.62 - 0.94]

Vujosevic S et al., 2009

0.93 [0.76 - 0.99]

Schiffman RM et al., 2005

0.95 [0.87 - 0.99]

Schiffman RM et al., 2005

0.81 [0.63 - 0.93]

Rudnisky CJ et al., 2007

0.80 [0.28 - 0.99]

Rudnisky CJ et al., 2007

0.99 [0.94 - 1.00]

Phiri R et al., 2006

0.86 [0.76 - 0.93]

Phiri R et al., 2006

0.71 [0.60 - 0.81]

Li HK et al., 2010

0.97 [0.88 - 1.00]

Li HK et al., 2010

0.94 [0.71 - 1.00]

Baeza DM et al., 2009

0.94 [0.79 - 0.99]

Baeza DM et al., 2009

0.98 [0.95 - 0.99]

COMBINED

0.92[0.86 - 0.96]

COMBINED

0.94[0.83 - 0.98]

Q = 23.62, df = 5.00, p = 0.00

I2 = 82.62 [70.69 - 94.56]
0.6

StudyId

Vujosevic S et al., 2009

Q = 34.53, df = 6.00, p = 0.00

I2 = 31.77 [0.00 - 90.05]
0.6

StudyId

Q = 67.81, df = 5.00, p = 0.00

I2 = 78.84 [62.21 - 95.46]
0.3

1.0
SENSITIVITY

I2 = 92.63 [88.27 - 96.98]
0.6

1.0
SPECIFICITY

Figure 2a Category 2 studies – sensitivity analysis excluding studies with Figure 2b Category 2 studies – sensitivity analysis excluding studies
published prior 2005
high/uncertain risk of bias as graded by QUADAS2 criteria
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Appendix G. Decision tree model for tele-ophthalmology versus in person examination
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Appendix H. Search strategy (Pubmed and EMBASE). Compliance after introduction of
mobile units for eye assessment and patient preferences for screening with mobile units

H.1 Medline
Search terms
1

*Telemedicine/ or exp Mobile Health Units/ or exp Community Pharmacy
Services/

2

(tele-medicine or tele-screening or telescreening or mobile health unit$ or
community pharmac$ service$).mp.

3

1 or 2

4

Eye diseases/ or Ophthalmology/ or Retinal Diseases/ or Retina/pa or exp
Diabetic Retinopathy/

5

(eye disease$ or retinal disease$ or retina$ or diabetic retinopath$).mp.

6

4 or 5

7

Mass Screening/ or diagnosis/ or early diagnosis/

8

3 and 6 and 7

H.2 Embase
Search terms
1

telediagnosis/ or telemedicine/ or preventive health service/

2

(telediagnos$ or telemedicine or tele-medicine or telescreening or telescreening or preventive health service$).mp.

3

1 or 2

4

eye disease/ or retina disease/ or diabetic retinopathy/

5

(eye disease$ or retina disease$ or retina$ or diabetic retinopath$).mp.

6

4 or 5

7

diagnosis/ or early diagnosis/ or exp mass screening/

8

3 and 6 and 7
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Appendix I. Calculation of model probabilities
I.1 Calculation of screening probabilities for in-person examination (Arm 1) and teleophthalmology (Arm 2)
I.1.1 In-person examination (Arm 1)
P(ref)= 0.511 Ontario examination rate of diabetic patients one year after receiving a
diabetes diagnosis (Buhrmann et al., 2003)
Proportion of non-compliant patients is defined as 1- P(ref) = 0.489
I.1.2 Tele-ophthalmology screening (Arm 2)
From the literature search (Appendix H) it is assumed a 10% volume increase (V) of
screening examinations after introduction of mobile retinal screening (Olayiwola JN et
al., 2011).
We have the following screening rate after introduction of tele-ophthalmology
P(Arm 2)= P(ref) х V
Where,
V= Volume increase of screening examinations after introduction of mobile retinal
screening.
P(Arm 2)= 0.511 x 1.10= 0.5621
I.1.2.1 Proportion of tele-ophthalmology examinations within Arm 2
To calculate the proportion of examinations with tele-ophthalmology within Arm 2 we
have the following
P(tele)= T ( P(ref) х V ) , V ≥ 1, P(tele) <1
Where,
T= Proportion of patients that accept a tele-ophthalmology examination
From the literature search (Appendix H) we assumed that 40% of screened patients
accepted a tele-ophthalmology examination (T), and the remaining 60% preferred the
in-person examination.
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P(tele)= 0.40 (0.5621)= 0.2248
I.1.2.2 Proportion of in-person examinations within Arm 2
The proportion of in-person examinations (P(inp)) is defined as
P(inp)= P(Arm 2) - P(tele)
P(inp)= 0.3373
I.1.2.3 Proportion of non-compliant patients
Proportion of non-compliant patients is defined as
P(nc)= 1- P(Arm2)
P(nc)= 0.4379
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Appendix J. Summary of probabilities incorporated in the economic model
Notation

Details

Value

p
1-p
q

Patients screened with current practice (Arm 1)
Patients not screened (Arm 1)
Patients would prefer in-person examination over
tele-ophthalmology

0.511
0.489
0.60

1-q
p(n)

Patients would prefer tele-ophthalmology
Patients screened after implementation of teleophthalmology (Arm 2)

0.40
0.5621

[p(n)]*[q]

Patients screened with in-person examination
(Arm 2)

0.3373

[p(n)]*[1-q]

Patients screened with tele-ophthalmology (Arm
2)
Patients not screened (after tele-ophthalmology)

0.2248

Test "+" (among diseased)
Test "-" (among diseased)
Test "-" (among non-diseased)
Test "+" (among non-diseased)

0.75
0.25
0.82
0.18

Patients with dilated examination
Patients with undilated examination
Unreadable images with pupil dilation
Readable images with pupil dilation
Unreadable images without dilation
Readable images without dilation
Test "+" (among diseased)
Test "-" (among diseased)
Test "-" (among non-diseased)
Test "+" (among non-diseased)

0.337
0.663
0.0547
0.9453
0.2874
0.7126
0.89
0.11
0.94
0.06

Proportion with any DR (prevalence)
Not diseased

0.225
0.775

Base tree

1-[(6)+(7)]
In-person examination
se_primary
1-[se_primary]
sp_primary
1-[sp_primary]
Tele-ophthalmology
d
1-d
u_d
1-[u_d]
u_nod
1-[u_nod]
se_tele
1-[se_tele]
sp_tele
1-[sp_tele]
DR_yes
1-[DR_yes]

0.4379
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Appendix K. Search strategy (Medline, Embase)
K.1 Medline
#

Search terms

1

Diabetic Retinopathy/ or macular edema/ or fundus oculi/

2

(diabetic retinopath$ or diabetic maculopath$ or macular edema or
macular oedema or fovea edema or fovea oedema or fundus
oculi).mp.

3

1 or 2

4

exp Diagnosis/ or diagnostic imaging/

5

(diagnos$ or screen$).mp.

6

4 or 5

7

"costs and cost analysis"/ or "cost allocation"/ or cost-benefit analysis/
or exp "cost control"/ or health care costs/ or direct service costs/ or
employer health costs/ or hospital costs/ or exp health expenditures/
or Decision Trees/ or markov chains/

8

(cost-effective$ or cost effective$ or cost-benefit or cost benefit or
decision tree$ or markov model$ or economic analys$).mp.

9

7 or 8

10

3 and 6 and 9

11

Diabetic Retinopathy/ec [Economics]

12

10 or 11

K.2 Embase
#

Search terms

1

Diabetic Retinopathy/ or retina macula edema/ or eye fundus/

2

(diabetic retinopath$ or diabetic maculopath$ or macular edema or
macular oedema or macula edema or macula oedema or fovea edema
or fovea oedema or fundus oculi).mp.

3

1 or 2

4

exp Diagnosis/ or diagnostic imaging/

5

diagnos$.mp.

6

4 or 5
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7

*"cost effectiveness analysis"/

8

economic evaluation/ or health care cost/ or decision tree/

9

7 or 8

10

(cost-effective$ or cost effective$ or decision tree$ or economic
analys$).mp.

11

9 or 10

12

3 and 6 and 11
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